<article article-type="research-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Microorganisms</journal-id><journal-id journal-id-type="iso-abbrev">Microorganisms</journal-id><journal-id journal-id-type="pmc-domain-id">3054</journal-id><journal-id journal-id-type="pmc-domain">microorg</journal-id><journal-id journal-id-type="publisher-id">microorganisms</journal-id><journal-title-group><journal-title>Microorganisms</journal-title></journal-title-group><issn pub-type="epub">2076-2607</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12844237</article-id><article-id pub-id-type="pmcid-ver">PMC12844237.1</article-id><article-id pub-id-type="pmcaid">12844237</article-id><article-id pub-id-type="pmcaiid">12844237</article-id><article-id pub-id-type="pmid">41597600</article-id><article-id pub-id-type="doi">10.3390/microorganisms14010078</article-id><article-id pub-id-type="publisher-id">microorganisms-14-00078</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Novel Quinolone JH62 (E-2-(Tridec-4-en-1-yl)-quinolin-4(1H)-one) from <italic toggle="yes">Pseudomonas aeruginosa</italic> Exhibits Potent Anticancer Activity</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Q">Qunyi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><xref ref-type="author-notes" rid="fn1-microorganisms-14-00078">†</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jianhe</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><xref ref-type="author-notes" rid="fn1-microorganisms-14-00078">†</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="X">Xiaoyan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiong</surname><given-names initials="L">Lantu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="L">Lianhui</given-names></name><xref ref-type="corresp" rid="c1-microorganisms-14-00078">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2630-8735</contrib-id><name name-style="western"><surname>Cui</surname><given-names initials="Z">Zining</given-names></name><xref ref-type="corresp" rid="c1-microorganisms-14-00078">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>d’Arminio Monforte</surname><given-names initials="A">Antonella</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-microorganisms-14-00078">Integrative Microbiology Research Centre, South China Agricultural University, Guangzhou 510642, China; <email>chenqy@stu.scau.edu.cn</email> (Q.C.); <email>jhwang@scau.edu.cn</email> (J.W.); <email>wuxy@stu.scau.edu.cn</email> (X.W.); <email>xionglt0618@stu.scau.edu.cn</email> (L.X.)</aff><author-notes><corresp id="c1-microorganisms-14-00078"><label>*</label>Correspondence: <email>lhzhang01@scau.edu.cn</email> (L.Z.); <email>ziningcui@scau.edu.cn</email> (Z.C.); Tel.: +86-13570466460 (L.Z.); +86-20-85288229 (Z.C.)</corresp><fn id="fn1-microorganisms-14-00078"><label>†</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><volume>14</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">506217</issue-id><elocation-id>78</elocation-id><history><date date-type="received"><day>23</day><month>11</month><year>2025</year></date><date date-type="rev-recd"><day>25</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-29 09:25:13.570"><day>29</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">Creative Commons Attribution (CC BY) license</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="microorganisms-14-00078.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><p>Cancer remains a leading cause of mortality worldwide, and new chemical leads are essential for developing potent anticancer therapies. Evidence suggests that <italic toggle="yes">Pseudomonas aeruginosa</italic> (<italic toggle="yes">Pa</italic>) may suppress tumorigenesis, although the underlying mechanisms remain largely unclear. This study characterized a novel small molecule quinolone, JH62 (E-2-(tridec-4-en-1-yl)-quinolin-4(1H)-one, C<sub>22</sub>H<sub>31</sub>NO), from <italic toggle="yes">Pa</italic>. JH62 exhibited broad-spectrum anticancer activity, inhibiting the proliferation of A549 lung cancer cells in a time- and dose-dependent manner with an IC<sub>50</sub> of 15 μM, while showed low cytotoxicity toward normal cells. In xenograft mice model, treatment with JH62 (10 mg/kg) reduced tumor weight and volume by 73% and 79%, respectively. Mechanistically, treatment with JH62 induced structural and functional disruption of mitochondria in cancer cells, triggered autophagic cell death, and did not cause DNA damage. Genetic analysis confirmed that JH62 biosynthesis depends on the <italic toggle="yes">pqsABCDE</italic> gene cluster and that JH62 positively regulates its own production. ADMET profiling further indicated promising drug-like properties for future development. These findings establish JH62 as a promising anticancer lead compound derived from microbial metabolism.</p></abstract><kwd-group><kwd>cancer therapy</kwd><kwd><italic toggle="yes">Pseudomonas aeruginosa</italic></kwd><kwd>A549 lung cancer cells</kwd><kwd>anticancer compounds</kwd><kwd>quinolone</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>U22A20480</award-id><award-id>32072450</award-id></award-group><award-group><funding-source>National Science Fund for Distinguished Young Scholars of Guangdong Province</funding-source><award-id>2021B1515020107</award-id></award-group><award-group><funding-source>Key Realm R&amp;D Program of Guangdong Province</funding-source><award-id>2020B0202090001</award-id></award-group><funding-statement>This research was funded by the National Natural Science Foundation of China (U22A20480; 32072450), the National Science Fund for Distinguished Young Scholars of Guangdong Province (2021B1515020107), and the Key Realm R&amp;D Program of Guangdong Province (2020B0202090001).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-microorganisms-14-00078" sec-type="intro"><title>1. Introduction</title><p>The complex interplay between microorganisms and human diseases has drawn increasing scientific attention in recent years. Microorganisms can disrupt host immune function and contribute to physiological and biochemical dysregulation, thereby accelerating disease onset and progression [<xref ref-type="bibr" rid="B1-microorganisms-14-00078">1</xref>]. For instance, <italic toggle="yes">Helicobacter pylori</italic> infection not only causes gastroenteritis and gastroduodenal ulcers, but also promotes the onset of gastric cancer [<xref ref-type="bibr" rid="B2-microorganisms-14-00078">2</xref>]. Gut bacterial disorder causes intestinal ailments, and is associated with diabetes, chronic heart diseases, cancers and obesity [<xref ref-type="bibr" rid="B3-microorganisms-14-00078">3</xref>]. Intriguingly, certain bacteria can also exert protective effects. Historical reports dating back over a century describe the use of <italic toggle="yes">Streptococcus</italic> cultures to inhibit tumor growth and improve patient outcomes [<xref ref-type="bibr" rid="B4-microorganisms-14-00078">4</xref>]. The abundance of <italic toggle="yes">Akkermansia muciniphila</italic> is significantly higher in healthy individuals compared to patients with obesity, diabetes, cardiovascular disease, and nonalcoholic fatty liver disease [<xref ref-type="bibr" rid="B5-microorganisms-14-00078">5</xref>]. <italic toggle="yes">Bifidobacterium</italic> spp. have been used for the treatment of acute diarrhea, necrotizing enterocolitis, and allergies [<xref ref-type="bibr" rid="B6-microorganisms-14-00078">6</xref>]. Modulation of the gut microbiome could potentially alleviate symptoms of Alzheimer’s disease [<xref ref-type="bibr" rid="B7-microorganisms-14-00078">7</xref>]. Apparently, understanding the underlying mechanisms by which microorganisms influence the progress of diseases may shed light and provide clues for disease prevention and control.</p><p>Due to the elevated incidence and mortality rates, cancer stands as one of the most lethal human diseases, posing a significant public health challenge on a global scale [<xref ref-type="bibr" rid="B8-microorganisms-14-00078">8</xref>]. Clinically, conventional cancer therapies, including chemotherapy, radiotherapy, and surgery, can effectively suppress cancer progression to a certain extent. However, these methods are limited by their side effects and recurrence rates [<xref ref-type="bibr" rid="B9-microorganisms-14-00078">9</xref>]. Therefore, the development of novel, effective therapies to complement or replace conventional treatments offers promising therapeutic options for millions of cancer patients [<xref ref-type="bibr" rid="B10-microorganisms-14-00078">10</xref>]. Among emerging approaches, microbe-mediated anticancer therapy represents a promising strategy, with microbial metabolites serving as a particularly attractive resource [<xref ref-type="bibr" rid="B11-microorganisms-14-00078">11</xref>]. For instance, Bleomycin, a glycopeptide produced by <italic toggle="yes">Streptoalloteichus hindustanus</italic>, has been used for squamous cell carcinomas, Hodgkin’s lymphomas, and testis tumors [<xref ref-type="bibr" rid="B12-microorganisms-14-00078">12</xref>]. <italic toggle="yes">Streptomyces spinoverrucosus</italic> produces galvaquinone B, which exhibited cytotoxicity against non-small-cell lung cancer (NSCLC) cell lines Calu-3 and H2887 [<xref ref-type="bibr" rid="B13-microorganisms-14-00078">13</xref>].</p><p>As a versatile opportunistic pathogen, <italic toggle="yes">Pseudomonas aeruginosa</italic> (<italic toggle="yes">Pa</italic>) is a primary source of hospital-acquired infections, associated with high morbidity and mortality in immunodeficient and cystic fibrosis (CF) patients [<xref ref-type="bibr" rid="B14-microorganisms-14-00078">14</xref>]. Intriguingly, epidemiological studies indicate that CF patients display a lower incidence of melanoma and breast cancer [<xref ref-type="bibr" rid="B15-microorganisms-14-00078">15</xref>,<xref ref-type="bibr" rid="B16-microorganisms-14-00078">16</xref>]. Experimentally, the supernatant of <italic toggle="yes">Pa</italic> could induce apoptosis in tumor-derived J774A.1 macrophages [<xref ref-type="bibr" rid="B17-microorganisms-14-00078">17</xref>], and a <italic toggle="yes">Pa</italic> clinical isolate was shown to trigger tumor cell necrosis via the TLR4-RIP3-MLKL pathway [<xref ref-type="bibr" rid="B18-microorganisms-14-00078">18</xref>]. These findings suggest that <italic toggle="yes">Pa</italic> may possess the ability to suppress tumorigenesis and tumor progression. Accordingly, a phase II clinical trial reported that the combination of inactivated <italic toggle="yes">Pa</italic> with Capecitabine improved the survival of metastatic breast cancer patients from 16.4 months to 25.4 months [<xref ref-type="bibr" rid="B19-microorganisms-14-00078">19</xref>]. A protein toxin exotoxin A produced by <italic toggle="yes">Pa</italic> showed potent anticancer activity both in vitro and in vivo, which inhibited protein synthesis through ADP-ribosylation of eukaryotic elongation factor 2 [<xref ref-type="bibr" rid="B20-microorganisms-14-00078">20</xref>]. Azurin, a periplasmic copper-containing redox protein secreted by <italic toggle="yes">Pa</italic>, exhibited strong cytotoxicity towards melanoma and breast cancer cells [<xref ref-type="bibr" rid="B21-microorganisms-14-00078">21</xref>]. However, exotoxin A and azurin are both proteins with large molecular weights, 66 kDa and 14 kDa, respectively, which may constrain their clinical applications.</p><p><italic toggle="yes">Pa</italic> possesses a relatively large genome and is capable of producing a broad-spectrum of secondary metabolites [<xref ref-type="bibr" rid="B22-microorganisms-14-00078">22</xref>]. The key metabolites of <italic toggle="yes">Pa</italic> are summarized in <xref ref-type="table" rid="microorganisms-14-00078-t001">Table 1</xref>. The biological activity of many secondary metabolites in <italic toggle="yes">Pa</italic> remains largely uncharacterized, representing an important and unexplored resource for identifying new potential anticancer compounds [<xref ref-type="bibr" rid="B23-microorganisms-14-00078">23</xref>]. Among diverse secondary metabolites, quinolone compounds produced by <italic toggle="yes">Pa</italic> have garnered sustained attention because of their remarkable structural diversity and broad biological activities. The isolation of quinolones from <italic toggle="yes">Pa</italic> dates back to the 1950s, with the initial identification of several antibiotic molecules such as HQNO, NQNO, HHQ, and NHQ [<xref ref-type="bibr" rid="B24-microorganisms-14-00078">24</xref>]. A pivotal advance came in 1999 with the discovery by Pesci et al. [<xref ref-type="bibr" rid="B25-microorganisms-14-00078">25</xref>] of the quorum sensing (QS) signal molecule PQS, which established quinolones as key regulators of bacterial communication. Advances in analytical technologies have since led to the characterization of numerous additional quinolone derivatives (e.g., UQNO, DHQ, AQNO), and it is now estimated that <italic toggle="yes">Pa</italic> produces over 50 structurally distinct quinolone compounds [<xref ref-type="bibr" rid="B26-microorganisms-14-00078">26</xref>,<xref ref-type="bibr" rid="B27-microorganisms-14-00078">27</xref>]. Beyond their role in QS, these molecules exhibit diverse bioactivities, including the modulation of virulence factor expression and direct interactions with host cells [<xref ref-type="bibr" rid="B28-microorganisms-14-00078">28</xref>]. Notably, during infection, <italic toggle="yes">Pa</italic>-derived quinolones such as PQS, HHQ, and HQNO can interfere with eukaryotic signaling pathways (e.g., NF-κB, HIF-1), thereby attenuating host innate immune responses [<xref ref-type="bibr" rid="B29-microorganisms-14-00078">29</xref>]. These findings underscore that <italic toggle="yes">Pa</italic>-derived quinolones function not only as bacterial signaling molecules but also as bioactive agents capable of modulating eukaryotic cell physiology. Despite this growing understanding, the potential effects of <italic toggle="yes">Pa</italic>-derived quinolones specifically on cancer cells remain largely unexplored, presenting a promising avenue for anticancer drug discovery.</p><p>In this study, we isolated and identified a novel compound, JH62, from <italic toggle="yes">Pa</italic> PAO1, which has promising potential as a targeted and low toxicity therapy agent against cancer. The results demonstrate that JH62 inhibits the growth and colony formation of A549 lung cancer cells in a time- and dose-dependent manner, with an IC<sub>50</sub> value of 15 μM. JH62 exhibits broad-spectrum anticancer activity by suppressing the proliferation of various cancer cell lines while showing low toxicity toward normal somatic cells. In xenograft mice, JH62 treatment significantly reduced both tumor volume and weight. Structural analysis via nuclear magnetic resonance (NMR) spectroscopy revealed JH62 to be E-2-(tridec-4-en-1-yl)-quinolin-4(1H)-one, with the chemical formula C<sub>22</sub>H<sub>31</sub>NO. Subsequent research revealed that JH62 induces mitochondrial functional and structural disruption in A549 lung cancer cells. Unlike the chemotherapeutic agent Doxorubicin (DOX), JH62 does not cause DNA damage. Analysis of the cell death pattern in A549 cells suggest the involvement of autophagy. We further confirmed that JH62 biosynthesis depends on the <italic toggle="yes">pqsABCDE</italic> gene cluster and that JH62 positively regulates its own production via feedback upregulation of this cluster. Favorable drug-like properties of JH62 were further supported by ADMET profiling. Together, these findings provide a scientific foundation for the development of JH62 as a promising anticancer lead compound.</p></sec><sec id="sec2-microorganisms-14-00078"><title>2. Materials and Methods</title><sec id="sec2dot1-microorganisms-14-00078"><title>2.1. Cell Lines</title><p>Different cells were utilized as follows: MEF: murine embryonic fibroblast (RRID: CVCL_L690); AML12: mouse liver cell lines (RRID: CVCL_0140); WI-38: human lung fibroblast cell lines (RRID: CVCL_0579); THLE-2: human liver epithelial cell lines (RRID: CVCL_3803); A549: human lung cancer cell lines (RRID: CVCL_0023); HEPG2: human liver cancer cell lines (RRID: CVCL_0027); HEP3B: human hepatoma cell lines (RRID: CVCL_0326); BxPC3: human pancreatic cancer cell lines (RRID: CVCL_0186); U87: human primary glioblastoma cell lines (RRID: CVCL_0022); DU145: human prostate cancer cell lines (RRID: CVCL_0105); MCF7: human breast cancer cell lines (RRID: CVCL_0031); HeLa: human cervical cancer cell lines (RRID: CVCL_0030); HCT116: human colon cancer cell lines (RRID: CVCL_0291). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with L-glutamine (Lonza) (2 mM), 10% fetal bovine serum (FBS, Hyclone), 1 × non-essential amino acids, and sodium pyruvate (1 mM). THLE-2 cells were maintained in THLE-2 Cell Complete Medium (Zhong Qiao Xin Zhou, Shanghai, China). Cells were incubated at 37 °C in a humidified incubator with 5% CO<sub>2</sub>. A549 cells were previously stored in the lab and other cell lines were a gift from Haishan Wang’s lab (Institute of Molecular and Cell Biology, Singapore). All cell lines were confirmed to be contamination-free.</p></sec><sec id="sec2dot2-microorganisms-14-00078"><title>2.2. Pa Strains</title><p>Different <italic toggle="yes">Pa</italic> strains were utilized as follows: <italic toggle="yes">Pa</italic> PAO1 was used as a parental strain for compound isolation, generation of mutants, and complementary strains. Other <italic toggle="yes">Pa</italic> strains (PAO1-1, PAO1-2, PAO1-3, PAO1-4, PAO1-5, CF4, PF4, NTU, PA14) were also from laboratory collections. All <italic toggle="yes">Pa</italic> strains were routinely grown at 37 °C in Luria-Bertani broth (LB).</p></sec><sec id="sec2dot3-microorganisms-14-00078"><title>2.3. Mice</title><p>The BALB/c nude mice were purchased from the Guangdong Medical Laboratory Animal Center (Guangzhou, China).</p></sec><sec id="sec2dot4-microorganisms-14-00078"><title>2.4. Reagents</title><p>DOX in aqueous solution was purchased from Sigma (Sigma-Aldrich, Singapore). JH62 was synthesized by U-CHEMO Holding Co., Limited (Hong Kong, China), based on reported procedures [<xref ref-type="bibr" rid="B51-microorganisms-14-00078">51</xref>]. The antibodies against LC3B were purchased from Abcam (Cambridge, UK).</p></sec><sec id="sec2dot5-microorganisms-14-00078"><title>2.5. Preparation of Bacterial Supernatants and Purification of Inhibitory Compound</title><p>Bacterial culture supernatants and inhibitory compounds were prepared and purified following previously described procedures with slight modifications [<xref ref-type="bibr" rid="B52-microorganisms-14-00078">52</xref>]. <italic toggle="yes">Pa</italic> PAO1 was grown overnight in LB as a starter culture. Bacterial cultures were adjusted to an OD600 of 1.0 and then inoculated (1% vol/vol) into fresh LB medium contained in 2 L glass conical flasks. Cultures were shaken at 200 rpm and 37 °C. Bacterial cultures were grown for 48 h. The total culture volume (20 L) was centrifuged and the bacterial supernatants were acidified to pH 3.5 by adding HCl, then extracted with an equal volume of ethyl acetate. The combined organic phases were evaporated to dryness, and the residue was dissolved in methanol (10 mL). The crude extracts were purified by HPLC using a C18 reverse-phase column (4.6 × 250 mm, Waters Corporation, Milford, MA, USA), eluted with an acetonitrile–water gradient (80:20 vol/vol) at a flow rate of 1 mL/min. Absorbance was monitored using a Waters 2487 Dual λ Absorbance Detector (Waters Corporation, Milford, MA, USA). Peaks corresponding to compounds of interest were collected and assayed for cytotoxicity against A549 cells.</p></sec><sec id="sec2dot6-microorganisms-14-00078"><title>2.6. Chemical Structural Analysis</title><p>Chemical structural analysis was performed by nuclear magnetic resonance (NMR) [<xref ref-type="bibr" rid="B53-microorganisms-14-00078">53</xref>]. NMR spectra were obtained using a Bruker Avance instrument (<sup>1</sup>H and <sup>13</sup>C NMR at 500 and 126 MHz; <sup>1</sup>H-<sup>13</sup>C NMR at 125 MHz), with chemical shifts referenced to the solvent peak. The product was further confirmed by high resolution mass spectrometry (HRMS) using negative ion mode electrospray ionization (MicrOTOF-QII, Bruker Daltonics, Bremen, Germany). Additionally, electron impact (EI) mass spectra were obtained at 20–40 eV.</p></sec><sec id="sec2dot7-microorganisms-14-00078"><title>2.7. Cell Viability</title><p>Cell viability was assessed using the WST-1 assay, based on a previously reported method with slight modifications [<xref ref-type="bibr" rid="B54-microorganisms-14-00078">54</xref>]. Briefly, cells were seeded at 1 × 10<sup>4</sup> cells per well in 96-well plates and then treated with different doses of JH62 or DOX for 0–72 h. The cells used included non-cancer cells (MEF, AML12, WI-38, and THLE-2) and cancer cells (A549, HEPG2, HEP3B, BxPC3, U87, DU145, MCF7, HeLa, and HCT116). The WST-1 reagent (Roche, Shanghai, China) was added to each well (10% vol/vol final concentration), followed by incubation for 3 h at 37 °C. Absorbance at OD450 was measured using a microplate reader (Synergy H1; BioTek Instruments, Winooski, VT, USA).</p></sec><sec id="sec2dot8-microorganisms-14-00078"><title>2.8. Drug Combination Study</title><p>The synergistic effect of JH62 and DOX was evaluated using a matrix-based combination study in 96-well plates, as previously described with minor modifications [<xref ref-type="bibr" rid="B55-microorganisms-14-00078">55</xref>]. Briefly, cells were seeded at 1 × 10<sup>4</sup> cells per well in 96-well plates. The cells used included non-cancer cells (MEF, AML12, WI-38, and THLE-2) and cancer cells (A549, HEPG2, HEP3B, BxPC3, U87, DU145, MCF7, HeLa, and HCT116). Serial dilutions of JH62 and DOX were prepared based on their predetermined individual IC<sub>50</sub> values. A concentration matrix was generated by combining each concentration of JH62 with each concentration of DOX, and the mixtures were applied to the cells. Cells treated with single agents or vehicle (DMSO) served as controls. After 24–48 h of incubation, cell viability was determined using the WST-1 assay according to the manufacturer’s protocol (Roche), and absorbance was measured at OD450 using a microplate reader.</p><p>Drug interaction was analyzed using the SynergyFinder web tool (<uri xlink:href="https://synergyfinder.fimm.fi/" xmlns:xlink="http://www.w3.org/1999/xlink">https://synergyfinder.fimm.fi/</uri>, accessed on 20 December 2025). The dose–response matrices were uploaded, and synergy scores were calculated using the Zero Interaction Potency (ZIP) model. According to the model’s criteria, a ZIP synergy score less than −10 indicates antagonism, a score between −10 and 10 indicates an additive effect, and a score greater than 10 indicates synergy.</p></sec><sec id="sec2dot9-microorganisms-14-00078"><title>2.9. Tumorigenicity Assay</title><p>Tumorigenicity assays were performed using BALB/c nude mice, adapted from previously described protocols with slight modifications [<xref ref-type="bibr" rid="B56-microorganisms-14-00078">56</xref>]. To establish the xenograft cancer model, cancer cells (1 × 10<sup>6</sup>) were subcutaneously injected into the right dorsal side of 6-week-old male BALB/c nude mice to induce tumor formation. The mice were randomly divided into 2 groups (<italic toggle="yes">n</italic> = 15). One group served as the control, and the other groups were treated with JH62 at doses of 10 mg/kg, via intraperitoneal injection twice a week. The mice in the control group were administered an equal volume of DMSO as the solvent control. The tumor sizes were measured weekly for three weeks. After that, the mice were sacrificed, and the tumors were isolated and weighed. All animal studies were approved by the Ethics Committee of South China Agricultural University.</p></sec><sec id="sec2dot10-microorganisms-14-00078"><title>2.10. Mitochondria JC-1 and MitoTracker Staining</title><p>Mitochondrial membrane potential and mitochondria localization were assessed by JC-1 and MitoTracker staining based on previously published methods [<xref ref-type="bibr" rid="B57-microorganisms-14-00078">57</xref>]. A549 cells were cultured at 37 °C and 5% CO<sub>2</sub> in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% heat-inactivated FBS (Thermo Fisher Scientific, Waltham, MA, USA) and L-Glutamine (Thermo Fisher Scientific, Waltham, MA, USA) (2 m<sc>M</sc>). An aliquot of 1 mL of JH62 (25 μ<sc>M</sc>) solution was added to the cell cultures. For JC-1 staining, cells grown in 24-well plates were treated as indicated for 12 h, washed with PBS, incubated with JC-1 solution according to the manufacturer’s instructions for 10 min at 37 °C, and then washed again. Cells were washed with dilution buffer, and photos were taken using a microscope. For MitoTracker staining, cells grown on 12 mm diameter round glass coverslips in 24-well plates were incubated with MitoTracker Red diluted 1:2000 or 1:20,000 from a stock solution (1 mM) in culture medium for 45 min at 37 °C. Cells were then washed with PBS and fixed with ice-cold 3.2% paraformaldehyde in PBS for 20 min at room temperature. After washing, coverslips were mounted on glass slides using an appropriate mounting medium. Photos were taken using a microscope.</p></sec><sec id="sec2dot11-microorganisms-14-00078"><title>2.11. Chromosome Staining Experiment</title><p>Metaphase chromosome spreads were prepared from A549 cells. Briefly, A549 cells were cultured. After treatment with JH62 or DOX, cells were incubated with Colcemid (Gibco BRL; 0.2 μg/mL final concentration) for 2 h to arrest cells in metaphase. Cells were then subjected to hypotonic treatment in KCl (0.075 <sc>M</sc>) at 37 °C for 5 min, and fixed by repeated washing with ice-cold freshly prepared 3:1 (vol/vol) methanol:acetic acid. Chromosome spreads were prepared on premarked glass slides using the “drop-cryo” protocol [<xref ref-type="bibr" rid="B58-microorganisms-14-00078">58</xref>]. The chromosome suspension was dropped onto a slide. This was followed by adding three drops of 45% acetic acid and placing a coverslip over the suspension. The slide was then inverted and placed on dry ice for 15 min. The spreads were postfixed in 2.5% glutaraldehyde in cacodylate buffer (pH 7.4, 75 m<sc>M</sc>) for 15 min and washed with cacodylate buffer (0.1 <sc>M</sc>). The chromosomes were stained with Vista Green DNA dye (Cell Biolabs, Singapore). After staining, the preparations were washed in water for 5, 10, and 15 min, then dehydrated using a series of ethanol solutions as follows: 5 min in a 70% solution, 10 min in an 85% solution, and 15 min in 100% ethanol. Finally, slides were mounted with a permanent mounting medium, sealed, and analyzed by microscopy.</p></sec><sec id="sec2dot12-microorganisms-14-00078"><title>2.12. DNA Fragmentation Analysis</title><p>Genomic DNA fragmentation was analyzed by agarose gel electrophoresis using previously described methods [<xref ref-type="bibr" rid="B59-microorganisms-14-00078">59</xref>]. A549 cells were seeded in 6 cm tissue culture dishes and cultured overnight. Before treatment with JH62 or DOX, the cells were cultured in DMEM lacking FBS for 16 h. After treatment, the cells were then washed three times with PBS and genomic DNA was extracted using a MasterPure™ DNA Purification Kit (Lucigen Corporation, Middleton, WI, USA). The DNA pellet was airdried and resuspended in Tris-HCl (pH 8.0, 10 m<sc>M</sc>). DNA samples (2.5 μg) were separated by 1% agarose gel electrophoresis in TAE buffer containing ethidium bromide.</p></sec><sec id="sec2dot13-microorganisms-14-00078"><title>2.13. Comet Assay</title><p>Residual DNA damage was detected by alkaline single cell gel electrophoresis (Comet Assay) using the Trevigen Comet Assay Kit (Trevigen, Gaithersburg, MD, USA) following the manufacturer’s protocol with slight modifications [<xref ref-type="bibr" rid="B60-microorganisms-14-00078">60</xref>]. Briefly, cells were grown in 6-well plates to approximately 30% confluence and treated with DOX or JH62 for 6 h. The treated cells were trypsinized and pelleted by centrifugation. The cell pellets were washed and resuspended in 2 mL of ice-cold PBS. The cell suspension was mixed 1:10 (vol/vol) with low-melting point agar at 42 °C and immediately pipetted onto a CometSlide™. Slides were incubated at 4 °C in the dark for 30 min, immersed in chilled lysis solution and incubated again at 4 °C for 30 min. Slides were placed in a horizontal electrophoresis chamber and electrophoresed with buffer NaOH (0.3 <sc>M</sc>) and EDTA (1 m<sc>M</sc>) at 1 V/cm for 15 min. Samples were dried and stained with Vista Green DNA dye (Cell Biolabs, Singapore). Comet tails were imaged using a model DM 2500 fluorescent microscope (Leica, Wetzlar, Germany) and quantified by Komet 5.5 software (Andor Technology, Belfast, UK). A minimum of 50 cells were scored per treatment. All experiments were performed independently in triplicate.</p></sec><sec id="sec2dot14-microorganisms-14-00078"><title>2.14. JH62 Extraction and Quantitative Analysis</title><p>The extraction and quantitative analysis of JH62 were performed based on previously published methods, with minor modifications [<xref ref-type="bibr" rid="B61-microorganisms-14-00078">61</xref>]. Corresponding <italic toggle="yes">Pa</italic> PAO1 and mutant strains were grown in LB medium at 37 °C overnight. An aliquot of 50 µL of bacterial culture (OD600 of 1.0) was diluted to 5 mL fresh LB medium in 50 mL tubes. The tubes were shaken at 37 °C. At the desired time point, culture supernatant was separated by centrifuging at 13,000 rpm for 5 min. Same volume of ethyl acetate with 0.1% acetic acid was added into the supernatant samples, and the samples were rapidly vortex mixed for 5 min. The organic phases were separated by centrifuging at 1000 rpm for 5 min, and transferred to new tubes. Acidified ethyl acetate was added into the sample, and the extraction was repeated again. All of the organic phases were collected together and evaporated to dryness. An aliquot of 200 µL of methanol was added to dissolve residues. The resulting solution was used for quantitative analysis of JH62.</p><p>Intracellular JH62 extraction was carried out by resuspending the cell pellet with 5 mL of fresh LB medium, followed by sonication disruption and centrifugation at 13,000 rpm for 5 min to obtain the disrupted supernatant. The same extraction described above was performed on the disrupted supernatant.</p><p>Liquid chromatography-mass spectrometry (LC-MS) was used for the quantitative analysis of JH62. Signal mass scans were set for JH62 at 326.2478 <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>. Data analysis was performed using Thermo Xcalibur software version 4.1.5 (Thermo Fisher Scientific, Waltham, MA, USA).</p></sec><sec id="sec2dot15-microorganisms-14-00078"><title>2.15. Construction of Pa Deletion Mutant and Complemented Strains</title><p>The construction of <italic toggle="yes">Pa</italic> deletion mutants and complemented strains was performed as previously described [<xref ref-type="bibr" rid="B62-microorganisms-14-00078">62</xref>]. For the generation of in-frame deletion mutants, the gene replacement vector pK18mobsacB derivatives, which were ligated with the 500bp upstream and 500 bp downstream sequences of target genes, were transformed into corresponding parental strains with the helper vector pRK2013 by triparental mating. Desired mutants were counter-selected on LB plates containing 10% sucrose and verified by PCR and DNA sequencing. For the construction of complementation and overexpression strains, the promoter and ORF region of target genes were cloned into pBBR1-MCS5 that had been digested, and then transformed into corresponding strains by triparental mating. All of the resultant constructs were confirmed by PCR analysis and DNA sequencing.</p></sec><sec id="sec2dot16-microorganisms-14-00078"><title>2.16. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Analysis</title><p>The ADMET analysis was conducted using the online platforms SwissADME (<uri xlink:href="http://www.swissadme.ch/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.swissadme.ch/</uri>, accessed on 10 May 2025) and ADMETlab 3.0 (<uri xlink:href="https://admetlab3.scbdd.com/" xmlns:xlink="http://www.w3.org/1999/xlink">https://admetlab3.scbdd.com/</uri>, accessed on 10 May 2025), following previously published protocols [<xref ref-type="bibr" rid="B63-microorganisms-14-00078">63</xref>].</p></sec><sec id="sec2dot17-microorganisms-14-00078"><title>2.17. Data Analysis</title><p>All data are presented as the mean ± SD (Standard deviation) of at least three independent experiments. Statistical analyses were performed using GraphPad Prism software version 9.5. Comparisons between two groups were conducted using the Student’s <italic toggle="yes">t</italic>-test, while comparisons among multiple groups were analyzed by one-way analysis of variance (ANOVA). Statistical significance was defined as <italic toggle="yes">p</italic> &lt; 0.05 (ns, not significant; * <italic toggle="yes">p</italic> &lt; 0.05; ** <italic toggle="yes">p</italic> &lt; 0.01; *** <italic toggle="yes">p</italic> &lt; 0.001; **** <italic toggle="yes">p</italic> &lt; 0.0001).</p></sec><sec id="sec2dot18-microorganisms-14-00078"><title>2.18. Ethics Statement</title><p>The animal study was reviewed and approved by the Ethics Committee of South China Agricultural University.</p></sec></sec><sec id="sec3-microorganisms-14-00078" sec-type="results"><title>3. Results</title><sec id="sec3dot1-microorganisms-14-00078"><title>3.1. A Novel Quinolone Compound JH62 Isolated from Pa Inhibits Cancer Cell Viability</title><p>Prompted by the finding that <italic toggle="yes">Pa</italic> is capable of inducing apoptosis and necrosis in several cancer cell lines [<xref ref-type="bibr" rid="B64-microorganisms-14-00078">64</xref>], we screened for small molecules with anticancer activity using A549 lung cancer cells, following the procedure outlined in <xref ref-type="fig" rid="microorganisms-14-00078-f001">Figure 1</xref>A. <italic toggle="yes">Pa</italic> PAO1 was cultured in LB medium for 48 h prior to extraction using acidified ethyl acetate. Crude extracts were separated through preparative HPLC, and 15 mL fractions were collected at 5 min intervals. The fractions were appropriately diluted and added to A549 cells growing in a 96-well plate. Cell viability was monitored daily by microscopy to identify fractions exhibiting cytotoxic activity. One active fraction, designated JH62, consistently inhibited the growth and proliferation of A549 cells. Microscopic examination showed that A549 cells treated with the JH62 crude fraction showed reduced adherence and failed to form a confluent monolayer (<xref ref-type="fig" rid="microorganisms-14-00078-f001">Figure 1</xref>B).</p><p>To analyze the chemical structure, the crude fraction containing JH62 was subjected to further separation and purification to obtain a relatively pure JH62 compound (<xref ref-type="app" rid="app1-microorganisms-14-00078">Figure S1</xref>). The chemical structure of JH62 was determined by 1D NMR (<sup>1</sup>H and <sup>13</sup>C) and 2D NMR (HMBC and HMQC) analysis, with key correlations in the 2D NMR spectra confirming the overall structure and the attachment of the side chain (<xref ref-type="fig" rid="microorganisms-14-00078-f001">Figure 1</xref>C–F and <xref ref-type="app" rid="app1-microorganisms-14-00078">Figure S2</xref>). JH62 was identified as E-2-(tridec-4-en-1-yl)-quinolin-4(1H)-one, a quinolone derivative featuring a 13-carbon unsaturated alkyl side chain. The chemical formula of JH62 is C<sub>22</sub>H<sub>31</sub>NO, with a molecular weight of 325.48 Da, identifying it as a quinolone compound that has not previously been reported in <italic toggle="yes">Pa</italic> (<xref ref-type="fig" rid="microorganisms-14-00078-f001">Figure 1</xref>G). For subsequent experiments, JH62 was custom-synthesized by U-CHEMO Holding Co., Limited (Hong Kong, China) following a reported synthetic procedure [<xref ref-type="bibr" rid="B51-microorganisms-14-00078">51</xref>], which describes the stepwise construction of the quinolone core and subsequent installation of the alkyl side chain. The synthesized JH62 compound exhibited identical UV spectral characteristics to the JH62 molecule purified from <italic toggle="yes">Pa</italic>, and its molecular weight and purity were confirmed by LC-MS analysis (<xref ref-type="app" rid="app1-microorganisms-14-00078">Figure S3</xref>).</p></sec><sec id="sec3dot2-microorganisms-14-00078"><title>3.2. JH62 Induces A549 Cell Death and Inhibits Tumor Growth</title><p>Further experiments were performed to understand the characteristics of JH62-induced cancer cell death. A549 cells were first treated with 25 μM of synthesized JH62 for 0, 4, 8, and 24 h. As shown in <xref ref-type="fig" rid="microorganisms-14-00078-f002">Figure 2</xref>A and <xref ref-type="app" rid="app1-microorganisms-14-00078">Figure S4</xref>, prolonged exposure to JH62 markedly attenuated proliferative capacity, leading to reduced cell adhesion, widened intercellular gaps, and failure to form confluent monolayers—an effect comparable to that of the apoptosis-inducing chemotherapeutic agent DOX [<xref ref-type="bibr" rid="B65-microorganisms-14-00078">65</xref>]. To assess the concentration-dependence of this inhibition, A549 cells were exposed to 12.5, 25, and 50 μM of JH62 for 24 h, which reduced viability by 20%, 48%, and 78%, respectively. After 32 h, viability decreased by 32%, 65%, and 84%, and after 48 h by 19%, 74%, and 92% (<xref ref-type="fig" rid="microorganisms-14-00078-f002">Figure 2</xref>B). Collectively, these data demonstrate that JH62 suppresses A549 cell proliferation in a time- and dose-dependent manner.</p><p>The cell colony formation assay, an in vitro method used to evaluate the proliferative capacity of cancer cells, was employed [<xref ref-type="bibr" rid="B66-microorganisms-14-00078">66</xref>]. Compared to the control group, treatment with 6.3 and 12.5 μM JH62 significantly reduced the number of A549 lung cancer cell colonies by 34% and 71%, respectively (<xref ref-type="fig" rid="microorganisms-14-00078-f002">Figure 2</xref>C,D).</p><p>Selective targeting of cancer cells is a key characteristic of potential anticancer drugs. Enhancing the specificity toward cancer cells while maintaining broad-spectrum anticancer activity is an important objective in anticancer drug development [<xref ref-type="bibr" rid="B67-microorganisms-14-00078">67</xref>]. To evaluate the spectrum and selectivity of JH62’s anticancer activity, we determined its half maximal inhibitory concentration (IC<sub>50</sub>) across a panel of non-cancer and cancer cell lines, using DOX as a reference chemotherapeutic agent (<xref ref-type="fig" rid="microorganisms-14-00078-f002">Figure 2</xref>E; <xref ref-type="table" rid="microorganisms-14-00078-t002">Table 2</xref>). In non-cancer cells, JH62 exhibited relatively high IC<sub>50</sub> values, including 47.2 ± 4.8 μM in MEF, 37.1 ± 0.7 μM in AML12, 44.1 ± 0.4 μM in WI-38, and 27.3 ± 4.9 μM in THLE-2, indicating low cytotoxicity toward non-cancer cells. In contrast, JH62 demonstrated significantly lower IC<sub>50</sub> values against a broad-spectrum of human cancer cell lines, 17.2 ± 0.6 μM for HEPG2 (liver), 10.8 ± 0.4 μM for HEP3B (liver), 15.0 ± 0.4 μM for BxPC3 (pancreatic), 10.0 ± 0.2 μM for U87 (glioblastoma), 13.8 ± 3.3 μM for DU145 (prostate), 14.8 ± 0.1 μM for A549 (lung), 13.9 ± 1.3 μM for MCF7 (breast), 13.6 ± 2.7 μM for HeLa (cervical), and 8.6 ± 0.1 μM for HCT116 (colon), suggesting broad-spectrum anticancer activity.</p><p>As a comparison, DOX exhibited substantially lower IC<sub>50</sub> values in both non-cancer and cancer cells. Specifically, IC<sub>50</sub> values of DOX ranged from 1.2 to 5.1 μM in non-cancer cells (MEF, AML12, WI-38, and THLE-2) and from 0.7 to 3.9 μM across the tested cancer cell lines (<xref ref-type="fig" rid="microorganisms-14-00078-f002">Figure 2</xref>F; <xref ref-type="table" rid="microorganisms-14-00078-t002">Table 2</xref>).</p><p>We next investigated potential synergistic interactions between JH62 and DOX, given their distinct mechanisms of action. A systematic combination study was performed by applying a concentration matrix based on their individual IC<sub>50</sub> values to the same panel of cell lines. Drug interaction was quantified using the Zero Interaction Potency (ZIP) model on the SynergyFinder web tool (<uri xlink:href="https://synergyfinder.fimm.fi/" xmlns:xlink="http://www.w3.org/1999/xlink">https://synergyfinder.fimm.fi/</uri>, accessed on 20 December 2025) (<xref ref-type="table" rid="microorganisms-14-00078-t002">Table 2</xref>). In non-cancer cells (MEF, AML12, WI-38), the combination of JH62 and DOX primarily resulted in an additive effect (ZIP score &lt; 10). An exception was noted in THLE-2 cells, which showed synergy (ZIP score &gt; 10). Importantly, a clear synergistic effect was observed in the majority of cancer cell lines tested, with ZIP scores ranging from 10 to 20. The interaction remained additive only in HEPG2 liver cancer cells and MCF7 breast cancer cells (ZIP score &lt; 10). These findings suggest that the combination of JH62 and DOX exerts a preferential synergistic effect against cancer cells.</p><p>To evaluate the efficacy of JH62 in inhibiting tumorigenesis in vivo, a cancer xenograft model was established by transplanting cancer cells into the right flank of nude mice. The mice were treated with JH62 (10 mg/kg body weight) twice weekly for three weeks, and tumor volume changes were regularly monitored during this period. External observations revealed that the tumor volume in the JH62-treated group was significantly smaller than that in the control group (<xref ref-type="fig" rid="microorganisms-14-00078-f002">Figure 2</xref>G and <xref ref-type="app" rid="app1-microorganisms-14-00078">Figure S5</xref>). The tumor growth curve indicated that tumors in the control group continued to enlarge, whereas those in the JH62-treated group remained largely at the initial level (<xref ref-type="fig" rid="microorganisms-14-00078-f002">Figure 2</xref>I). After 20 days of treatment, the average weight of solid tumors in the JH62-treated group was 186.3 mg, compared to 693.4 mg in the control group. The average tumor size in the control group was approximately 900 mm<sup>3</sup>, while in the JH62-treated group, it was only about 190 mm<sup>3</sup> (<xref ref-type="fig" rid="microorganisms-14-00078-f002">Figure 2</xref>H,I).</p></sec><sec id="sec3dot3-microorganisms-14-00078"><title>3.3. JH62 Induces Mitochondrial Dysfunction and Structural Disruption in A549 Lung Cancer Cells</title><p>In cancer cells, mitochondria serve as central organelles for energy production and survival, critically influencing cell viability, immune evasion, tumor progression, and therapy resistance [<xref ref-type="bibr" rid="B68-microorganisms-14-00078">68</xref>]. Given that JH62 inhibits A549 lung cancer cell growth, we next investigated its effects on mitochondrial integrity. The mitochondrial membrane potential (ΔΨm), resulting from the charge distribution across the inner mitochondrial membrane, is a key factor in maintaining normal mitochondrial function, and its collapse is a critical indicator of mitochondrial dysfunction [<xref ref-type="bibr" rid="B69-microorganisms-14-00078">69</xref>]. We used the potential-sensitive fluorescent probe JC-1, which emits green fluorescence as a monomer at low concentrations and forms red-fluorescent aggregates in mitochondria with intact ΔΨm [<xref ref-type="bibr" rid="B70-microorganisms-14-00078">70</xref>]. After treating A549 cells with JH62, the red fluorescence began to decrease within 2–3 h and reached the lowest level by 4 h, indicating that JH62 treatment disrupted the mitochondrial membrane potential (<xref ref-type="fig" rid="microorganisms-14-00078-f003">Figure 3</xref>A and <xref ref-type="app" rid="app1-microorganisms-14-00078">Figure S6</xref>).</p><p>MitoTracker Red staining further revealed altered mitochondrial morphology and distribution following JH62 exposure. In JH62-treated cells, the MitoTracker Red signal transitioned from an initially focal, punctate, or circular pattern to a diffuse cytoplasmic distribution. Fluorescence intensity was significantly reduced, characteristic mitochondrial structures disappeared, and morphology became indistinct, suggesting that JH62 treatment led to the loss of mitochondrial membrane potential and disruption of structural integrity (<xref ref-type="fig" rid="microorganisms-14-00078-f003">Figure 3</xref>B).</p><p>Transmission electron microscopy (TEM) provided ultrastructural confirmation. In control cells, mitochondria exhibited intact morphology with clearly visible cristae. In contrast, mitochondria in JH62-treated cells commonly showed pathological alterations such as swelling, blurred inner membrane structures, and disrupted cristae (<xref ref-type="fig" rid="microorganisms-14-00078-f003">Figure 3</xref>C). These findings indicate that JH62 induces severe mitochondrial damage in lung cancer cells.</p></sec><sec id="sec3dot4-microorganisms-14-00078"><title>3.4. JH62 Induces Autophagic Cell Death Distinct from DOX-Mediated Apoptosis</title><p>DOX, a widely used chemotherapeutic agent, can trigger multiple forms of cell death including apoptosis, ferroptosis, and pyroptosis [<xref ref-type="bibr" rid="B71-microorganisms-14-00078">71</xref>]. Although both JH62 and DOX induced death in A549 cells (<xref ref-type="fig" rid="microorganisms-14-00078-f001">Figure 1</xref>A), this study aimed to compare the modes of cell death induced by these two compounds. After 18 h of JH62 treatment, A549 cells became swollen, bubble-like structures emerged in the vicinity of the nucleus, and these vacuoles accumulated in the cytoplasm as the cytosol became transparent with prolonged exposure to JH62 (<xref ref-type="fig" rid="microorganisms-14-00078-f004">Figure 4</xref>A). In contrast, as previously reported [<xref ref-type="bibr" rid="B72-microorganisms-14-00078">72</xref>], DOX-treated A549 cells showed a shrinking morphology, the formation of apoptotic bodies, and plasma membrane blebbing (<xref ref-type="fig" rid="microorganisms-14-00078-f004">Figure 4</xref>A).</p><p>A key mechanism of DOX is the induction of DNA damage [<xref ref-type="bibr" rid="B73-microorganisms-14-00078">73</xref>]. The chromosome staining experiments showed that the chromosomes of DOX-treated A549 cells were fragmented and adhered together, whereas the chromosome of JH62-treated cells maintained normal morphology similar to the control (<xref ref-type="fig" rid="microorganisms-14-00078-f004">Figure 4</xref>B). The genomic DNA electrophoresis assays demonstrated that genomic DNA integrity remained unchanged even after 24 h of JH62 treatment (5–100 µM), whereas DOX treatment resulted in obvious DNA fragmentation (<xref ref-type="fig" rid="microorganisms-14-00078-f004">Figure 4</xref>C). Comet tail analysis further confirmed the maintenance of DNA integrity following JH62 treatment, while DOX-treated samples produced a distinct and typical comet tail (<xref ref-type="fig" rid="microorganisms-14-00078-f004">Figure 4</xref>D). The above findings demonstrate that JH62 treatment did not trigger the DOX-like DNA damage.</p><p>DOX can induce both apoptosis and necrosis in cancer cells, and the cytotoxic effects can be effectively suppressed by the apoptosis inhibitor zVAD-fmk and the necroptosis inhibitor Nec-1 [<xref ref-type="bibr" rid="B74-microorganisms-14-00078">74</xref>]. Therefore, we investigated whether zVAD-fmk and Nec-1 could attenuate JH62-induced cell death in A549 lung cancer cells. As shown in <xref ref-type="fig" rid="microorganisms-14-00078-f004">Figure 4</xref>E, neither zVAD-fmk nor Nec-1, whether applied individually or in combination, could reverse the cytotoxicity of JH62 in A549 cells. These results indicate that the cell death triggered by JH62 is not associated with apoptosis or necroptosis.</p><p>We next investigated whether autophagy contributes to JH62-induced cell death. Microscopic observation revealed abundant translucent circular structures resembling autophagosomes in JH62-treated A549 cells, which were absent in the controls (<xref ref-type="fig" rid="microorganisms-14-00078-f004">Figure 4</xref>F). Immunofluorescence staining for LC3B, a core autophagy marker [<xref ref-type="bibr" rid="B75-microorganisms-14-00078">75</xref>], showed that JH62 treatment progressively increased both the intensity and number of LC3B puncta—a hallmark of autophagosome formation—over 2–24 h, whereas control cells exhibited only a diffuse, weak LC3B signal (<xref ref-type="fig" rid="microorganisms-14-00078-f004">Figure 4</xref>G). These findings suggest that JH62 upregulates LC3B expression and promotes its punctate aggregation, supporting the conclusion that JH62 induces autophagic cell death in lung cancer cells.</p></sec><sec id="sec3dot5-microorganisms-14-00078"><title>3.5. The pqs Gene Cluster Mediates JH62 Biosynthesis in Pa</title><p>The biosynthetic pathway of JH62, a previously uncharacterized quinolone in <italic toggle="yes">Pa</italic>, was investigated. Time–course analysis by liquid chromatography-mass spectrometry (LC-MS) revealed that extracellular JH62 production correlated with bacterial density, peaking during the mid- to late-logarithmic growth phase (~10 h; <xref ref-type="fig" rid="microorganisms-14-00078-f005">Figure 5</xref>A). Furthermore, 66.5% of total JH62 was detected in the culture supernatant, with the remaining 33.5% associated with the cell pellet, indicating active secretion (<xref ref-type="fig" rid="microorganisms-14-00078-f005">Figure 5</xref>B).</p><p><italic toggle="yes">Pa</italic> synthesizes over 50 structurally diverse quinolones via the <italic toggle="yes">pqs</italic> gene cluster (<xref ref-type="app" rid="app1-microorganisms-14-00078">Figure S7A</xref>) [<xref ref-type="bibr" rid="B76-microorganisms-14-00078">76</xref>]. Given the structural similarity of JH62 to known <italic toggle="yes">pqs</italic>-dependent quinolones such as HHQ and PQS (<xref ref-type="app" rid="app1-microorganisms-14-00078">Figure S7B</xref>), in-frame deletion mutants of the <italic toggle="yes">pqs</italic> gene and the corresponding complemented strains were constructed. The results of quantitative experiments showed that JH62 production was abolished in Δ<italic toggle="yes">pqsA</italic>, Δ<italic toggle="yes">pqsB</italic>, Δ<italic toggle="yes">pqsC</italic>, Δ<italic toggle="yes">pqsD</italic>, and Δ<italic toggle="yes">pqsE</italic> mutants and restored upon complementation (<xref ref-type="fig" rid="microorganisms-14-00078-f005">Figure 5</xref>C). Among these, <italic toggle="yes">pqsA</italic> was identified as the rate-limiting step, as its overexpression significantly enhanced JH62 yield (<xref ref-type="fig" rid="microorganisms-14-00078-f005">Figure 5</xref>D). Furthermore, the production of JH62 exhibited differentiation across various <italic toggle="yes">Pa</italic> strains (<xref ref-type="fig" rid="microorganisms-14-00078-f005">Figure 5</xref>E). Notably, heterologous expression of the entire <italic toggle="yes">pqsABCDE</italic> cluster in the non-producing strain PAO1-1 resulted in JH62 levels twice those of wild-type (WT) PAO1 (<xref ref-type="fig" rid="microorganisms-14-00078-f005">Figure 5</xref>F).</p><p>Since the <italic toggle="yes">pqs</italic> gene cluster is responsible for JH62 biosynthesis, we determined whether JH62 itself could regulate the expression of this cluster, potentially establishing a feedback loop. To this end, we supplemented the JH62-deficient Δ<italic toggle="yes">pqsA</italic> mutant with exogenous JH62 and assessed the <italic toggle="yes">pqs</italic> cluster transcription. The results demonstrate that JH62 markedly upregulated the transcription of <italic toggle="yes">pqsA</italic>, <italic toggle="yes">pqsB</italic>, <italic toggle="yes">pqsC</italic>, <italic toggle="yes">pqsD</italic>, and <italic toggle="yes">pqsE</italic>, while leaving <italic toggle="yes">pqsH</italic> transcription unaffected, indicating a positive feedback loop that amplifies its production (<xref ref-type="fig" rid="microorganisms-14-00078-f005">Figure 5</xref>G).</p><p>Since JH62 accumulation is density-dependent and the <italic toggle="yes">pqs</italic> cluster is linked to QS, we evaluated the influence of two other QS systems, <italic toggle="yes">las</italic> and <italic toggle="yes">rhl</italic> [<xref ref-type="bibr" rid="B77-microorganisms-14-00078">77</xref>], on JH62 production. The results showed that JH62 production was significantly decreased in Δ<italic toggle="yes">lasI</italic> and Δ<italic toggle="yes">lasR</italic>, and increased in Δ<italic toggle="yes">rhlI</italic> and Δ<italic toggle="yes">rhlR</italic> (<xref ref-type="fig" rid="microorganisms-14-00078-f005">Figure 5</xref>H). These results suggest that JH62 biosynthesis is integrated into the QS network and provide genetic strategies for enhancing its yield.</p></sec><sec id="sec3dot6-microorganisms-14-00078"><title>3.6. ADMET Evaluation Identifies JH62 as a Promising Lead Compound for Drug Development</title><p>Assessment of drug-like properties and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties is essential for predicting in vivo pharmacokinetics and aiding clinical translation [<xref ref-type="bibr" rid="B78-microorganisms-14-00078">78</xref>]. Accordingly, we conducted ADMET analysis on JH62 by using the online tools in websites SwissADME and ADMETlab 3.0. As summarized in <xref ref-type="table" rid="microorganisms-14-00078-t003">Table 3</xref>, JH62 exhibits suitable physicochemical parameters such as low molecular weight (&lt;500), topological surface area (&lt;140 Å<sup>2</sup>), molar refractivity (&lt;130), number of hydrogen bond donors (&lt;5), and number of hydrogen bond acceptors (&lt;10). The medicinal chemistry suggests that JH62 complies with Lipinski’s and “Golden Triangle” rules, supporting its drug-like properties. In addition, JH62 is predicted to be synthetically accessible, with a synthetic accessibility score well below 5. The ADMET evaluations revealed that JH62 exhibits favorable permeability, high bioavailability, and low toxicity. Structurally, JH62 did not trigger any PAINS (Pan Assay Interference Structures) alert. However, the Brenk method identified a structural alert related to the presence of an isolated alkene reactive group, which implies that JH62 has room for structural optimization. Collectively, these in silico data support JH62 as a promising and druggable lead candidate for anticancer development.</p></sec></sec><sec id="sec4-microorganisms-14-00078" sec-type="discussion"><title>4. Discussion</title><p>Research on quinolone-type small molecules from <italic toggle="yes">Pa</italic> dates back to the 1950s [<xref ref-type="bibr" rid="B24-microorganisms-14-00078">24</xref>]. Advances in detection and analytical techniques, particularly mass spectrometry-based metabolomic profiling, suggest that <italic toggle="yes">Pa</italic> may produce over 50 structurally diverse quinolone compounds, all sharing a 4-quinolone core [<xref ref-type="bibr" rid="B79-microorganisms-14-00078">79</xref>]. In this study, we isolated a novel quinolone compound, JH62, from <italic toggle="yes">Pa</italic> and determined its structure as E-2-(tridec-4-en-1-yl)-quinolin-4(1H)-one (C<sub>22</sub>H<sub>31</sub>NO, molecular weight 325.48 Da). JH62 features a trans-4-tridecene side chain attached to the conserved quinolone core, representing a novel member of the <italic toggle="yes">Pa</italic>-derived quinolone family. The well-characterized quinolones produced by <italic toggle="yes">Pa</italic>, including HHQ and PQS, are established QS signal molecules that play crucial roles in regulating bacterial virulence, secondary metabolism, and interspecies interactions [<xref ref-type="bibr" rid="B80-microorganisms-14-00078">80</xref>]. Structurally, JH62 shares the conserved quinolone core scaffold with these canonical QS molecules (<xref ref-type="app" rid="app1-microorganisms-14-00078">Figure S7B</xref>), raising the possibility that it may interact with QS-related chemical frameworks. Indeed, beyond its anticancer properties, preliminary data indicate that JH62 also exhibits bioactivities related to QS and virulence regulation in <italic toggle="yes">Pa</italic>. Despite this shared scaffold, JH62 exhibits notable structural distinctions compared with previously characterized <italic toggle="yes">Pa</italic> quinolones. In particular, JH62 possesses an unusually long alkyl side chain comprising 13 carbon atoms, which represents the longest side chain reported to date among the experimentally isolated quinolone metabolites from this bacterium. Moreover, the position of the double bond within the alkyl chain differs from those of canonical QS molecules, further underscoring its structural uniqueness and expanding the known chemical diversity of <italic toggle="yes">Pa</italic>-derived quinolones. Earlier mass spectrometric analyses suggested the possible existence of C13-alkyl quinolones in <italic toggle="yes">Pa</italic> [<xref ref-type="bibr" rid="B81-microorganisms-14-00078">81</xref>]; however, the isolation and structural characterization of JH62 provide direct experimental evidence for this quinolone subclass. The biosynthesis of all quinolone compounds in <italic toggle="yes">Pa</italic> depends on the multi-enzyme system encoded by the <italic toggle="yes">pqs</italic> gene cluster. The putative biosynthesis pathway of JH62 is shown in <xref ref-type="app" rid="app1-microorganisms-14-00078">Figure S7C</xref>. In this context, JH62 represents a structurally distinct member of the bacterial quinolone family that links a QS-associated chemical scaffold with pronounced anticancer activity. While the present study focuses on its anticancer properties, a detailed investigation of potential QS-related or virulence-modulatory functions of JH62 will be addressed in future studies.</p><p>To contextualize the anticancer activity of JH62 within the JH62-type bacterial metabolites, we have noticed the growing reports on JH62-type compounds with similar bioactivity. Indeed, several quinolones produced by <italic toggle="yes">Pa</italic> itself possess anticancer properties. For instance, the well-known QS molecule PQS exhibits an IC<sub>50</sub> of 19 μM against A549 cells, and both PQS and HHQ have been shown to impair mitochondrial function—a mechanism that aligns with our observations for JH62 [<xref ref-type="bibr" rid="B82-microorganisms-14-00078">82</xref>,<xref ref-type="bibr" rid="B83-microorganisms-14-00078">83</xref>]. Other <italic toggle="yes">Pa</italic>-derived quinolones also demonstrate anticancer effects, albeit often with lower potency (IC<sub>50</sub> values typically ranging from 20 to 200 μM) [<xref ref-type="bibr" rid="B84-microorganisms-14-00078">84</xref>]. Beyond <italic toggle="yes">Pa</italic>, quinolones from diverse bacterial genera show promising anticancer potential. Notable examples include 8-hydroxyquinoline from <italic toggle="yes">Streptomyces</italic> sp. (IC<sub>50</sub> 26 μM against A549) [<xref ref-type="bibr" rid="B85-microorganisms-14-00078">85</xref>], E-3-methyl-2-(2-octenyl)-4-quinolone from <italic toggle="yes">Burkholderia</italic> sp. (active against MCF7, HeLa, HT1080, and SiHa cells with IC<sub>50</sub> values from 0.24 to 37 μM) [<xref ref-type="bibr" rid="B86-microorganisms-14-00078">86</xref>], and E-1-hydroxy-2-(non-2-enyl)-3-methyl-4-quinolone from <italic toggle="yes">Arthrobacter</italic> sp. (IC<sub>50</sub> 1.9 μM against HeLa) [<xref ref-type="bibr" rid="B87-microorganisms-14-00078">87</xref>], and three quinolones from a sponge-associated <italic toggle="yes">Pseudomonas</italic> species (IC<sub>50</sub> values of 33, 16, and 6 μM against KB cells) [<xref ref-type="bibr" rid="B88-microorganisms-14-00078">88</xref>]. Clioquinol (5-chloro-7-iodo-8-hydroxyquinoline), which shares a structural similarity with JH62, also inhibits the growth of various cancer cell lines with IC<sub>50</sub> values ranging from 6 to 43 μM [<xref ref-type="bibr" rid="B89-microorganisms-14-00078">89</xref>]. This collective evidence underscores that the quinolone scaffold is a privileged structure for anticancer discovery [<xref ref-type="bibr" rid="B90-microorganisms-14-00078">90</xref>], yet JH62 compares favorably with previously reported quinolone compounds, exhibiting low IC<sub>50</sub> values (&lt;20 μM) across a broad panel of cancer cell lines. Together with its structural uniqueness and selective cytotoxicity toward cancer cells, these observations further support the therapeutic potential of bacterial quinolones and positions JH62 as a particularly promising lead within this structural family.</p><p>The favorable safety profile of a drug candidate is paramount for successful clinical translation. In this study, JH62 exhibited high IC<sub>50</sub> values (&gt;25 μM) across murine (MEF and AML12) and human (WI-38 and THLE-2) non-cancer cell lines, indicating low cytotoxicity toward normal cells. In contrast, it demonstrated significantly greater potency (IC<sub>50</sub> &lt; 20 μM) against a diverse panel of cancer cell lines derived from lung, liver, breast, colon, and other tissues. This selectivity between normal and cancer cells—validated here in human models—suggests that JH62 can effectively target cancer cells while sparing normal ones, which is a highly desirable feature for anticancer agents aimed at minimizing off-target effects. For comparison, DOX showed consistently low IC<sub>50</sub> values (ranging from 0.5 to 5 μM) against both non-cancer and cancer cells. The differential selectivity of JH62 highlights its potential for an improved therapeutic window compared to conventional chemotherapeutics like DOX. Furthermore, the broad-spectrum activity of JH62 against cancers of various origins strengthens its promise as a versatile lead compound for further development.</p><p>Previous work reported that <italic toggle="yes">Pa</italic> PAO1 can induce non-apoptotic cell death, though the mechanism remained unclear [<xref ref-type="bibr" rid="B91-microorganisms-14-00078">91</xref>]. Our findings suggest that JH62-induced cell death is not apoptosis-associated and is accompanied by mitochondrial morphology and functional abnormalities, pointing toward a non-apoptotic death mechanism. It is important to note that the evidence supporting JH62-induced autophagic cell death in this study is primarily based on morphological observations (e.g., accumulation of autophagosome-like vesicles) and the punctate aggregation of the autophagy marker LC3B. While these findings strongly suggest the involvement of autophagy, further validation through pharmacological inhibition (e.g., using autophagy inhibitors) is warranted to conclusively establish the causal relationship between autophagy activation and JH62-mediated cytotoxicity. These experiments are currently underway. Establishing the precise role of autophagy will be a key focus of our ongoing research, which aims to delineate the complete molecular cascade triggered by JH62. Elucidating this pathway will not only solidify our understanding of JH62’s mechanism of action but may also reveal novel targets for combination therapies, particularly in cancers resistant to conventional apoptosis-inducing agents.</p><p>Pharmacokinetic profiling predicts the ADMET properties of a drug candidate [<xref ref-type="bibr" rid="B92-microorganisms-14-00078">92</xref>]. JH62 possesses suitable physicochemical properties; its C13 alkyl side chain does not significantly impair its absorption, distribution, or permeability, indicating its promising potential as an anticancer lead compound. It is noteworthy that in silico prediction indicates a high PPB rate (~99%) for JH62, which could imply a low free drug concentration and potential limitations in pharmacological availability. However, a high PPB does not inherently preclude therapeutic efficacy. This is exemplified by numerous clinically successful drugs with a PPB exceeding 98%, such as warfarin and phenytoin, which remain effective in vivo. According to the free drug hypothesis and dynamic pharmacokinetic principles, a high PPB does not necessarily reduce the unbound drug concentration at the target site as it is often counterbalanced by corresponding adjustments in systemic clearance [<xref ref-type="bibr" rid="B93-microorganisms-14-00078">93</xref>]. Critically, the potent activity of JH62 observed both in vitro and in vivo indicates that biologically effective concentrations can be achieved at the site of action.</p><p>The ADMET predictions presented in this study are derived from in silico analyses, which, while informative for early stage screening, necessitate experimental validation to fully characterize the compound’s pharmacokinetic and safety profile, as rightly noted. In light of this, our ongoing research is strategically focused on the structural optimization of the JH62 scaffold, aiming to enhance both its anticancer efficacy and druggability. We are conducting systematic structure–activity relationship (SAR) studies, exploring modifications such as the introduction of electron donating/withdrawing groups and variations in the alkyl side chain length. Encouragingly, preliminary results indicate that certain modifications, like the introduction of a methoxy group, reduce the predicted PPB to approximately 90% while increasing anticancer activity by approximately 41%. In subsequent studies, experimental evaluation of ADMET-related parameters, including hERG liability, microsomal stability, metabolic soft spots, and physicochemical properties such as solubility and logD, will be performed for JH62 and its optimized derivatives. Comprehensive experimental ADMET profiling and lead optimization will be addressed in future investigations to further support the development of JH62 as a promising anticancer lead compound.</p><p>Beyond its core anticancer activity, preliminary exploratory observations suggest that JH62 may influence STAT3-related signaling pathways, which raises the possibility that JH62 could exert additional effects related to inflammation or immune regulation. The STAT3 signaling axis represents a central regulatory node linking cancer development and inflammatory responses. However, the primary scope of the present work is the discovery and characterization of JH62 as a novel anticancer agent. Comprehensive evaluation of the anti-inflammatory potential and broader immunomodulatory effects of JH62 will be addressed in future investigations.</p><p>The discovery of JH62 provides evidence for the field of microbe-mediated anticancer therapy. Interkingdom interactions of microbiota in cancer therapy are therefore an important future direction, but the underlying mechanisms remain elusive and need extensive validation via preclinical models and clinical trials.</p></sec><sec id="sec5-microorganisms-14-00078" sec-type="conclusions"><title>5. Conclusions</title><p>This study identified a novel and potent anticancer compound, JH62, from <italic toggle="yes">Pa</italic>. JH62 inhibited the proliferation and clonogenicity of lung cancer cells in a time- and dose-dependent manner, exhibited broad-spectrum anticancer activity with low cytotoxicity toward normal cells, and suppressed tumor growth in vivo. Treatment with JH62 induced mitochondrial morphological and functional disruption in cancer cells. The cell death triggered by JH62 is associated with autophagy. The biosynthesis of JH62 depends on the <italic toggle="yes">pqs</italic> gene cluster in <italic toggle="yes">Pa</italic>, and JH62 positively regulates the expression of this cluster. Together with favorable drug-like properties predicted by ADMET profiling, these findings establish JH62 as a promising lead compound for anticancer drug development.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-microorganisms-14-00078"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/microorganisms14010078/s1" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.mdpi.com/article/10.3390/microorganisms14010078/s1</uri>, Figure S1: HPLC separation and purification process of JH62; Figure S2: The full NMR spectrum of JH62; Figure S3: Comparative analysis of synthetic and purified JH62; Figure S4: Confocal microscope images of JH62-treated A549 cells; Figure S5: Tumor growth in xenograft mouse model with JH62 treatment; Figure S6: Mitochondrial JC-1 aggregate detection of mitochondria in JH62-treated A549 cells; Figure S7: Quinolone compounds biosynthesized by the <italic toggle="yes">pqs</italic> gene cluster of <italic toggle="yes">Pa</italic>.</p><supplementary-material content-type="local-data" id="microorganisms-14-00078-s001" orientation="portrait" position="float"><media orientation="portrait" position="float" xlink:href="microorganisms-14-00078-s001.zip" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, L.Z. and Z.C.; Methodology, Q.C., J.W. and X.W.; Investigation, Q.C., J.W., X.W. and L.X.; writing—original draft, Q.C. and J.W.; writing—review and editing, L.Z. and Z.C.; funding acquisition, L.Z. and Z.C.; supervision, L.Z. and Z.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Ethics Committee of South China Agricultural University. Approval ID: SYXK2022-0136. Approval Date: 1 June 2022.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article/<xref ref-type="app" rid="app1-microorganisms-14-00078">Supplementary Materials</xref>. Further inquiries can be directed to the corresponding authors.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" colspan="1" rowspan="1" valign="middle">AQNO</td><td align="left" colspan="1" rowspan="1" valign="middle">2-alkyl-4-hydroxyquinoline N-oxide</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">DHQ</td><td align="left" colspan="1" rowspan="1" valign="middle">2, 4-dihydroxyquinoline</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">DMSO</td><td align="left" colspan="1" rowspan="1" valign="middle">Dimethyl sulfoxide</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">DOX</td><td align="left" colspan="1" rowspan="1" valign="middle">Doxorubicin</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">HHQ</td><td align="left" colspan="1" rowspan="1" valign="middle">2-heptyl-4-hydroxyquinoline</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">HNQ</td><td align="left" colspan="1" rowspan="1" valign="middle">2-nonyl-4-hydroxyquinoline</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">HPLC</td><td align="left" colspan="1" rowspan="1" valign="middle">High Performance Liquid Chromatography</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">HQNO</td><td align="left" colspan="1" rowspan="1" valign="middle">2-heptyl-4-hydroxyquinoline N-oxide</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">IC<sub>50</sub></td><td align="left" colspan="1" rowspan="1" valign="middle">Half maximal inhibitory concentration</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">LC-MS</td><td align="left" colspan="1" rowspan="1" valign="middle">Liquid chromatography-mass spectrometry</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">NMR</td><td align="left" colspan="1" rowspan="1" valign="middle">Nuclear magnetic resonance</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">NQNO</td><td align="left" colspan="1" rowspan="1" valign="middle">2-nonyl-4-hydroxyquinoline N-oxide</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle"><italic toggle="yes">Pa</italic></td><td align="left" colspan="1" rowspan="1" valign="middle"><italic toggle="yes">Pseudomonas aeruginosa</italic></td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">PPB</td><td align="left" colspan="1" rowspan="1" valign="middle">Plasma protein binding</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">PQS</td><td align="left" colspan="1" rowspan="1" valign="middle">2-heptyl-3-hydroxy-4(1H)-quinolone</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">UQNO</td><td align="left" colspan="1" rowspan="1" valign="middle">2-undecyl-4-hydroxyquinoline N-oxide</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">WT</td><td align="left" colspan="1" rowspan="1" valign="middle">Wild type</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-microorganisms-14-00078"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cho</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Blaser</surname><given-names>M.J.</given-names></name>
</person-group><article-title>The human microbiome: At the interface of health and disease</article-title><source>Nat. Rev. Genet.</source><year>2012</year><volume>13</volume><fpage>260</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1038/nrg3182</pub-id><pub-id pub-id-type="pmid">22411464</pub-id><pub-id pub-id-type="pmcid">PMC3418802</pub-id></element-citation></ref><ref id="B2-microorganisms-14-00078"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Elbehiry</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Marzouk</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Aldubaib</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Abalkhail</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Anagreyyah</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Anajirih</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Almuzaini</surname><given-names>A.M.</given-names></name>
<name name-style="western"><surname>Rawway</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Alfadhel</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Draz</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> infection: Current status and future prospects on diagnostic, therapeutic and control challenges</article-title><source>Antibiotics</source><year>2023</year><volume>12</volume><elocation-id>191</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12020191</pub-id><pub-id pub-id-type="pmid">36830102</pub-id><pub-id pub-id-type="pmcid">PMC9952126</pub-id></element-citation></ref><ref id="B3-microorganisms-14-00078"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>Y.-J.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Gan</surname><given-names>R.-Y.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>D.-P.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>H.-B.</given-names></name>
</person-group><article-title>Impacts of gut bacteria on human health and diseases</article-title><source>Int. J. Mol. Sci.</source><year>2015</year><volume>16</volume><fpage>7493</fpage><lpage>7519</lpage><pub-id pub-id-type="doi">10.3390/ijms16047493</pub-id><pub-id pub-id-type="pmid">25849657</pub-id><pub-id pub-id-type="pmcid">PMC4425030</pub-id></element-citation></ref><ref id="B4-microorganisms-14-00078"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Coley</surname><given-names>W.B.</given-names></name>
</person-group><article-title>The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893</article-title><source>Clin. Orthop. Relat. Res.</source><year>1991</year><volume>98</volume><fpage>563</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">1984929</pub-id></element-citation></ref><ref id="B5-microorganisms-14-00078"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Niu</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Zogona</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Xing</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Cui</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Liang</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name>
</person-group><article-title><italic toggle="yes">Akkermansia muciniphila</italic>: A potential candidate for ameliorating metabolic diseases</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1370658</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1370658</pub-id><pub-id pub-id-type="pmid">38571945</pub-id><pub-id pub-id-type="pmcid">PMC10987721</pub-id></element-citation></ref><ref id="B6-microorganisms-14-00078"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Di Gioia</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Aloisio</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Mazzola</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Biavati</surname><given-names>B.</given-names></name>
</person-group><article-title><italic toggle="yes">Bifidobacteria</italic>: Their impact on gut microbiota composition and their applications as probiotics in infants</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2014</year><volume>98</volume><fpage>563</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1007/s00253-013-5405-9</pub-id><pub-id pub-id-type="pmid">24287935</pub-id></element-citation></ref><ref id="B7-microorganisms-14-00078"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hazan</surname><given-names>S.</given-names></name>
</person-group><article-title>Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: A case report</article-title><source>J. Int. Med. Res.</source><year>2020</year><volume>48</volume><fpage>0300060520925930</fpage><pub-id pub-id-type="doi">10.1177/0300060520925930</pub-id><pub-id pub-id-type="pmid">32600151</pub-id><pub-id pub-id-type="pmcid">PMC7328362</pub-id></element-citation></ref><ref id="B8-microorganisms-14-00078"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Deo</surname><given-names>S.V.S.</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name>
</person-group><article-title>GLOBOCAN 2020 report on global cancer burden: Challenges and opportunities for surgical oncologists</article-title><source>Ann. Surg. Oncol.</source><year>2022</year><volume>29</volume><fpage>6497</fpage><lpage>6500</lpage><pub-id pub-id-type="doi">10.1245/s10434-022-12151-6</pub-id><pub-id pub-id-type="pmid">35838905</pub-id></element-citation></ref><ref id="B9-microorganisms-14-00078"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Miller</surname><given-names>K.D.</given-names></name>
<name name-style="western"><surname>Nogueira</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Devasia</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Mariotto</surname><given-names>A.B.</given-names></name>
<name name-style="western"><surname>Yabroff</surname><given-names>K.R.</given-names></name>
<name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kramer</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Cancer treatment and survivorship statistics, 2022</article-title><source>CA A Cancer J. Clin.</source><year>2022</year><volume>72</volume><fpage>409</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.3322/caac.21731</pub-id><pub-id pub-id-type="pmid">35736631</pub-id></element-citation></ref><ref id="B10-microorganisms-14-00078"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hashem</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ali</surname><given-names>T.A.</given-names></name>
<name name-style="western"><surname>Akhtar</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Nisar</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Sageena</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Ali</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Al-Mannai</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Therachiyil</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Mir</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Elfaki</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>150</volume><fpage>113054</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113054</pub-id><pub-id pub-id-type="pmid">35658225</pub-id></element-citation></ref><ref id="B11-microorganisms-14-00078"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ji</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Si</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Song</surname><given-names>W.</given-names></name>
</person-group><article-title>Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria</article-title><source>Adv. Drug Deliv. Rev.</source><year>2024</year><volume>211</volume><fpage>115345</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2024.115345</pub-id><pub-id pub-id-type="pmid">38834140</pub-id></element-citation></ref><ref id="B12-microorganisms-14-00078"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cort</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Timur</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ozdemir</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Ozben</surname><given-names>T.</given-names></name>
</person-group><article-title>Effects of curcumin on bleomycin-induced apoptosis in human malignant testicular germ cells</article-title><source>J. Physiol. Biochem.</source><year>2013</year><volume>69</volume><fpage>289</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1007/s13105-012-0211-x</pub-id><pub-id pub-id-type="pmid">23001851</pub-id></element-citation></ref><ref id="B13-microorganisms-14-00078"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Martinez</surname><given-names>E.D.</given-names></name>
<name name-style="western"><surname>MacMillan</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Anthraquinones from a marine-derived <italic toggle="yes">Streptomyces spinoverrucosus</italic></article-title><source>J. Nat. Prod.</source><year>2012</year><volume>75</volume><fpage>1759</fpage><lpage>1764</lpage><pub-id pub-id-type="doi">10.1021/np3004326</pub-id><pub-id pub-id-type="pmid">23057874</pub-id><pub-id pub-id-type="pmcid">PMC3488424</pub-id></element-citation></ref><ref id="B14-microorganisms-14-00078"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tuon</surname><given-names>F.F.</given-names></name>
<name name-style="western"><surname>Dantas</surname><given-names>L.R.</given-names></name>
<name name-style="western"><surname>Suss</surname><given-names>P.H.</given-names></name>
<name name-style="western"><surname>Tasca Ribeiro</surname><given-names>V.S.</given-names></name>
</person-group><article-title>Pathogenesis of the <italic toggle="yes">Pseudomonas aeruginosa</italic> biofilm: A review</article-title><source>Pathogens</source><year>2022</year><volume>11</volume><elocation-id>300</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11030300</pub-id><pub-id pub-id-type="pmid">35335624</pub-id><pub-id pub-id-type="pmcid">PMC8950561</pub-id></element-citation></ref><ref id="B15-microorganisms-14-00078"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Abraham</surname><given-names>E.H.</given-names></name>
<name name-style="western"><surname>Vos</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Kahn</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Grubman</surname><given-names>S.A.</given-names></name>
<name name-style="western"><surname>Jefferson</surname><given-names>D.M.</given-names></name>
<name name-style="western"><surname>Ding</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Okunieff</surname><given-names>P.</given-names></name>
</person-group><article-title>Cystic fibrosis hetero- and homozygosity is associated with inhibition of breast cancer growth</article-title><source>Nat. Med.</source><year>1996</year><volume>2</volume><fpage>593</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1038/nm0596-593</pub-id><pub-id pub-id-type="pmid">8616723</pub-id></element-citation></ref><ref id="B16-microorganisms-14-00078"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Maisonneuve</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Marshall</surname><given-names>B.C.</given-names></name>
<name name-style="western"><surname>Knapp</surname><given-names>E.A.</given-names></name>
<name name-style="western"><surname>Lowenfels</surname><given-names>A.B.</given-names></name>
</person-group><article-title>Cancer risk in cystic fibrosis: A 20-year nationwide study from the United States</article-title><source>JNCI J. Natl. Cancer Inst.</source><year>2013</year><volume>105</volume><fpage>122</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1093/jnci/djs481</pub-id><pub-id pub-id-type="pmid">23178438</pub-id></element-citation></ref><ref id="B17-microorganisms-14-00078"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Yamada</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Goto</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Punj</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Zaborina</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Kimbara</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Das Gupta</surname><given-names>T.K.</given-names></name>
<name name-style="western"><surname>Chakrabarty</surname><given-names>A.M.</given-names></name>
</person-group><article-title>The bacterial redox protein azurin induces apoptosis in J774 macrophages through complex formation and stabilization of the tumor suppressor protein p53</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>7054</fpage><lpage>7062</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.12.7054-7062.2002</pub-id><pub-id pub-id-type="pmid">12438386</pub-id><pub-id pub-id-type="pmcid">PMC133031</pub-id></element-citation></ref><ref id="B18-microorganisms-14-00078"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Qi</surname><given-names>J.-L.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>J.-R.</given-names></name>
<name name-style="western"><surname>Jin</surname><given-names>S.-M.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Bai</surname><given-names>H.-M.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>C.-B.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>Y.-B.</given-names></name>
</person-group><article-title><italic toggle="yes">P. aeruginosa</italic> mediated necroptosis in mouse tumor cells induces long-lasting systemic antitumor immunity</article-title><source>Front. Oncol.</source><year>2021</year><volume>10</volume><elocation-id>610651</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.610651</pub-id><pub-id pub-id-type="pmid">33643911</pub-id><pub-id pub-id-type="pmcid">PMC7908819</pub-id></element-citation></ref><ref id="B19-microorganisms-14-00078"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lv</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Shao</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Phase II study of <italic toggle="yes">Pseudomonas aeruginosa</italic>-mannose-sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0118607</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0118607</pub-id><pub-id pub-id-type="pmid">25768439</pub-id><pub-id pub-id-type="pmcid">PMC4359133</pub-id></element-citation></ref><ref id="B20-microorganisms-14-00078"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wolf</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Elsaesser-Beile</surname><given-names>U.</given-names></name>
</person-group><article-title><italic toggle="yes">Pseudomonas</italic> exotoxin A: From virulence factor to anti-cancer agent</article-title><source>Int. J. Med. Microbiol.</source><year>2009</year><volume>299</volume><fpage>161</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2008.08.003</pub-id><pub-id pub-id-type="pmid">18948059</pub-id></element-citation></ref><ref id="B21-microorganisms-14-00078"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Shu</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Qin</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Su</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name>
</person-group><article-title>Anticancer actions of azurin and its derived peptide p28</article-title><source>Protein J.</source><year>2020</year><volume>39</volume><fpage>182</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1007/s10930-020-09891-3</pub-id><pub-id pub-id-type="pmid">32180097</pub-id></element-citation></ref><ref id="B22-microorganisms-14-00078"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ghssein</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Ezzeddine</surname><given-names>Z.</given-names></name>
</person-group><article-title>A review of <italic toggle="yes">Pseudomonas aeruginosa</italic> metallophores: Pyoverdine, pyochelin and pseudopaline</article-title><source>Biology</source><year>2022</year><volume>11</volume><elocation-id>1711</elocation-id><pub-id pub-id-type="doi">10.3390/biology11121711</pub-id><pub-id pub-id-type="pmid">36552220</pub-id><pub-id pub-id-type="pmcid">PMC9774294</pub-id></element-citation></ref><ref id="B23-microorganisms-14-00078"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Si</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Guan</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name>
</person-group><article-title>Progress in the study of natural antimicrobial active substances in <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Molecules</source><year>2024</year><volume>29</volume><elocation-id>4400</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29184400</pub-id><pub-id pub-id-type="pmid">39339396</pub-id><pub-id pub-id-type="pmcid">PMC11434294</pub-id></element-citation></ref><ref id="B24-microorganisms-14-00078"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wells</surname><given-names>I.C.</given-names></name>
<name name-style="western"><surname>Elliott</surname><given-names>W.H.</given-names></name>
<name name-style="western"><surname>Thayer</surname><given-names>S.A.</given-names></name>
<name name-style="western"><surname>Doisy</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Ozonization of some antibiotic substances produced by <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Biol. Chem.</source><year>1952</year><volume>196</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)55736-7</pub-id><pub-id pub-id-type="pmid">12980973</pub-id></element-citation></ref><ref id="B25-microorganisms-14-00078"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Pesci</surname><given-names>E.C.</given-names></name>
<name name-style="western"><surname>Milbank</surname><given-names>J.B.</given-names></name>
<name name-style="western"><surname>Pearson</surname><given-names>J.P.</given-names></name>
<name name-style="western"><surname>McKnight</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Kende</surname><given-names>A.S.</given-names></name>
<name name-style="western"><surname>Greenberg</surname><given-names>E.P.</given-names></name>
<name name-style="western"><surname>Iglewski</surname><given-names>B.H.</given-names></name>
</person-group><article-title>Quinolone signaling in the cell-to-cell communication system of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>11229</fpage><lpage>11234</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.20.11229</pub-id><pub-id pub-id-type="pmid">10500159</pub-id><pub-id pub-id-type="pmcid">PMC18016</pub-id></element-citation></ref><ref id="B26-microorganisms-14-00078"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bredenbruch</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Nimtz</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Wray</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Morr</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Müller</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Häussler</surname><given-names>S.</given-names></name>
</person-group><article-title>Biosynthetic pathway of <italic toggle="yes">Pseudomonas aeruginosa</italic> 4-hydroxy-2-alkylquinolines</article-title><source>J. Bacteriol.</source><year>2005</year><volume>187</volume><fpage>3630</fpage><lpage>3635</lpage><pub-id pub-id-type="doi">10.1128/JB.187.11.3630-3635.2005</pub-id><pub-id pub-id-type="pmid">15901684</pub-id><pub-id pub-id-type="pmcid">PMC1112037</pub-id></element-citation></ref><ref id="B27-microorganisms-14-00078"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lépine</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Déziel</surname><given-names>E.</given-names></name>
</person-group><article-title>Liquid chromatography/mass spectrometry for the detection and quantification of N-acyl-L-homoserine lactones and 4-hydroxy-2-alkylquinolines</article-title><source>Methods Mol. Biol.</source><year>2011</year><volume>692</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/978-1-60761-971-0_5</pub-id><pub-id pub-id-type="pmid">21031304</pub-id></element-citation></ref><ref id="B28-microorganisms-14-00078"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name>
</person-group><article-title>The <italic toggle="yes">Pseudomonas</italic> quinolone signal (PQS): Not just for quorum sensing anymore</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2018</year><volume>8</volume><elocation-id>230</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2018.00230</pub-id><pub-id pub-id-type="pmid">30023354</pub-id><pub-id pub-id-type="pmcid">PMC6039570</pub-id></element-citation></ref><ref id="B29-microorganisms-14-00078"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Legendre</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Reen</surname><given-names>F.J.</given-names></name>
<name name-style="western"><surname>Mooij</surname><given-names>M.J.</given-names></name>
<name name-style="western"><surname>McGlacken</surname><given-names>G.P.</given-names></name>
<name name-style="western"><surname>Adams</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>O’Gara</surname><given-names>F.</given-names></name>
</person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> Alkyl quinolones repress hypoxia-inducible factor 1 (HIF-1) signaling through HIF-1α degradation</article-title><source>Infect. Immun.</source><year>2012</year><volume>80</volume><fpage>3985</fpage><lpage>3992</lpage><pub-id pub-id-type="doi">10.1128/IAI.00554-12</pub-id><pub-id pub-id-type="pmid">22949552</pub-id><pub-id pub-id-type="pmcid">PMC3486049</pub-id></element-citation></ref><ref id="B30-microorganisms-14-00078"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Jayaseelan</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ramaswamy</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Dharmaraj</surname><given-names>S.</given-names></name>
</person-group><article-title>Pyocyanin: Production, applications, challenges and new insights</article-title><source>World J. Microbiol. Biotechnol.</source><year>2014</year><volume>30</volume><fpage>1159</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1007/s11274-013-1552-5</pub-id><pub-id pub-id-type="pmid">24214679</pub-id></element-citation></ref><ref id="B31-microorganisms-14-00078"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Vilaplana</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Marco</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Phenazines as potential biomarkers of <italic toggle="yes">Pseudomonas aeruginosa</italic> infections: Synthesis regulation, pathogenesis and analytical methods for their detection</article-title><source>Anal. Bioanal. Chem.</source><year>2020</year><volume>412</volume><fpage>5897</fpage><lpage>5912</lpage><pub-id pub-id-type="doi">10.1007/s00216-020-02696-4</pub-id><pub-id pub-id-type="pmid">32462363</pub-id></element-citation></ref><ref id="B32-microorganisms-14-00078"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chong</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name>
</person-group><article-title>Microbial production of rhamnolipids: Opportunities, challenges and strategies</article-title><source>Microb. Cell Fact.</source><year>2017</year><volume>16</volume><fpage>137</fpage><pub-id pub-id-type="doi">10.1186/s12934-017-0753-2</pub-id><pub-id pub-id-type="pmid">28779757</pub-id><pub-id pub-id-type="pmcid">PMC5544971</pub-id></element-citation></ref><ref id="B33-microorganisms-14-00078"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kang</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Revtovich</surname><given-names>A.V.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Shah</surname><given-names>K.N.</given-names></name>
<name name-style="western"><surname>Cannon</surname><given-names>C.L.</given-names></name>
<name name-style="western"><surname>Kirienko</surname><given-names>N.V.</given-names></name>
</person-group><article-title>Pyoverdine-dependent virulence of <italic toggle="yes">Pseudomonas aeruginosa</italic> isolates from cystic fibrosis patients</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><elocation-id>2048</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.02048</pub-id><pub-id pub-id-type="pmid">31551982</pub-id><pub-id pub-id-type="pmcid">PMC6743535</pub-id></element-citation></ref><ref id="B34-microorganisms-14-00078"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kaplan</surname><given-names>A.R.</given-names></name>
<name name-style="western"><surname>Musaev</surname><given-names>D.G.</given-names></name>
<name name-style="western"><surname>Wuest</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Pyochelin biosynthetic metabolites bind iron and promote growth in <italic toggle="yes">Pseudomonads</italic> demonstrating siderophore-like activity</article-title><source>ACS Infect. Dis.</source><year>2021</year><volume>7</volume><fpage>544</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00897</pub-id><pub-id pub-id-type="pmid">33577297</pub-id><pub-id pub-id-type="pmcid">PMC8322966</pub-id></element-citation></ref><ref id="B35-microorganisms-14-00078"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Spaněl</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Gilchrist</surname><given-names>F.J.</given-names></name>
<name name-style="western"><surname>Lenney</surname><given-names>W.</given-names></name>
</person-group><article-title>Hydrogen cyanide, a volatile biomarker of <italic toggle="yes">Pseudomonas aeruginosa</italic> infection</article-title><source>J. Breath Res.</source><year>2013</year><volume>7</volume><fpage>044001</fpage><pub-id pub-id-type="doi">10.1088/1752-7155/7/4/044001</pub-id><pub-id pub-id-type="pmid">24287489</pub-id></element-citation></ref><ref id="B36-microorganisms-14-00078"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>
</person-group><article-title>The hierarchy quorum sensing network in <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Protein Cell</source><year>2015</year><volume>6</volume><fpage>26</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s13238-014-0100-x</pub-id><pub-id pub-id-type="pmid">25249263</pub-id><pub-id pub-id-type="pmcid">PMC4286720</pub-id></element-citation></ref><ref id="B37-microorganisms-14-00078"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Diggle</surname><given-names>S.P.</given-names></name>
<name name-style="western"><surname>Cornelis</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Williams</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Cámara</surname><given-names>M.</given-names></name>
</person-group><article-title>4-quinolone signalling in <italic toggle="yes">Pseudomonas aeruginosa</italic>: Old molecules, new perspectives</article-title><source>Int. J. Med. Microbiol. IJMM</source><year>2006</year><volume>296</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2006.01.038</pub-id><pub-id pub-id-type="pmid">16483840</pub-id></element-citation></ref><ref id="B38-microorganisms-14-00078"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Leid</surname><given-names>J.G.</given-names></name>
<name name-style="western"><surname>Willson</surname><given-names>C.J.</given-names></name>
<name name-style="western"><surname>Shirtliff</surname><given-names>M.E.</given-names></name>
<name name-style="western"><surname>Hassett</surname><given-names>D.J.</given-names></name>
<name name-style="western"><surname>Parsek</surname><given-names>M.R.</given-names></name>
<name name-style="western"><surname>Jeffers</surname><given-names>A.K.</given-names></name>
</person-group><article-title>The exopolysaccharide alginate protects <italic toggle="yes">Pseudomonas aeruginosa</italic> biofilm bacteria from IFN-gamma-mediated macrophage killing</article-title><source>J. Immunol.</source><year>2005</year><volume>175</volume><fpage>7512</fpage><lpage>7518</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.11.7512</pub-id><pub-id pub-id-type="pmid">16301659</pub-id></element-citation></ref><ref id="B39-microorganisms-14-00078"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Marmont</surname><given-names>L.S.</given-names></name>
<name name-style="western"><surname>Rich</surname><given-names>J.D.</given-names></name>
<name name-style="western"><surname>Whitney</surname><given-names>J.C.</given-names></name>
<name name-style="western"><surname>Whitfield</surname><given-names>G.B.</given-names></name>
<name name-style="western"><surname>Almblad</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Robinson</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Parsek</surname><given-names>M.R.</given-names></name>
<name name-style="western"><surname>Harrison</surname><given-names>J.J.</given-names></name>
<name name-style="western"><surname>Howell</surname><given-names>P.L.</given-names></name>
</person-group><article-title>Oligomeric lipoprotein PelC guides Pel polysaccharide export across the outer membrane of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>2892</fpage><lpage>2897</lpage><pub-id pub-id-type="doi">10.1073/pnas.1613606114</pub-id><pub-id pub-id-type="pmid">28242707</pub-id><pub-id pub-id-type="pmcid">PMC5358405</pub-id></element-citation></ref><ref id="B40-microorganisms-14-00078"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Jackson</surname><given-names>K.D.</given-names></name>
<name name-style="western"><surname>Landry</surname><given-names>R.M.</given-names></name>
<name name-style="western"><surname>Parsek</surname><given-names>M.R.</given-names></name>
<name name-style="western"><surname>Wozniak</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Analysis of <italic toggle="yes">Pseudomonas aeruginosa</italic> conditional psl variants reveals roles for the psl polysaccharide in adhesion and maintaining biofilm structure postattachment</article-title><source>J. Bacteriol.</source><year>2006</year><volume>188</volume><fpage>8213</fpage><lpage>8221</lpage><pub-id pub-id-type="doi">10.1128/JB.01202-06</pub-id><pub-id pub-id-type="pmid">16980452</pub-id><pub-id pub-id-type="pmcid">PMC1698210</pub-id></element-citation></ref><ref id="B41-microorganisms-14-00078"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dolan</surname><given-names>S.K.</given-names></name>
<name name-style="western"><surname>Kohlstedt</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Trigg</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Vallejo Ramirez</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Kaminski</surname><given-names>C.F.</given-names></name>
<name name-style="western"><surname>Wittmann</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Welch</surname><given-names>M.</given-names></name>
</person-group><article-title>Contextual flexibility in <italic toggle="yes">Pseudomonas aeruginosa</italic> central carbon metabolism during growth in single carbon sources</article-title><source>mBio</source><year>2020</year><volume>11</volume><fpage>e02684-19</fpage><pub-id pub-id-type="doi">10.1128/mBio.02684-19</pub-id><pub-id pub-id-type="pmid">32184246</pub-id><pub-id pub-id-type="pmcid">PMC7078475</pub-id></element-citation></ref><ref id="B42-microorganisms-14-00078"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sauvage</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Gaviard</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Tahrioui</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Coquet</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Le</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Alexandre</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ben Abdelkrim</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bouffartigues</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Lesouhaitier</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Chevalier</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Impact of carbon source supplementations on <italic toggle="yes">Pseudomonas aeruginosa</italic> physiology</article-title><source>J. Proteome Res.</source><year>2022</year><volume>21</volume><fpage>1392</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.1c00936</pub-id><pub-id pub-id-type="pmid">35482949</pub-id></element-citation></ref><ref id="B43-microorganisms-14-00078"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lundgren</surname><given-names>B.R.</given-names></name>
<name name-style="western"><surname>Shoytush</surname><given-names>J.M.</given-names></name>
<name name-style="western"><surname>Scheel</surname><given-names>R.A.</given-names></name>
<name name-style="western"><surname>Sain</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Sarwar</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Nomura</surname><given-names>C.T.</given-names></name>
</person-group><article-title>Utilization of L-glutamate as a preferred or sole nutrient in <italic toggle="yes">Pseudomonas aeruginosa</italic> PAO1 depends on genes encoding for the enhancer-binding protein AauR, the sigma factor RpoN and the transporter complex AatJQMP</article-title><source>BMC Microbiol.</source><year>2021</year><volume>21</volume><elocation-id>83</elocation-id><pub-id pub-id-type="doi">10.1186/s12866-021-02145-x</pub-id><pub-id pub-id-type="pmid">33722201</pub-id><pub-id pub-id-type="pmcid">PMC7962211</pub-id></element-citation></ref><ref id="B44-microorganisms-14-00078"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mahmud</surname><given-names>S.A.</given-names></name>
<name name-style="western"><surname>Qureshi</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Sapkota</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Pellegrino</surname><given-names>M.W.</given-names></name>
</person-group><article-title>A pathogen branched-chain amino acid catabolic pathway subverts host survival by impairing energy metabolism and the mitochondrial UPR</article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><elocation-id>e1008918</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008918</pub-id><pub-id pub-id-type="pmid">32997715</pub-id><pub-id pub-id-type="pmcid">PMC7549759</pub-id></element-citation></ref><ref id="B45-microorganisms-14-00078"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lu</surname><given-names>C.D.</given-names></name>
<name name-style="western"><surname>Itoh</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Nakada</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Functional analysis and regulation of the divergent <italic toggle="yes">spuABCDEFGH</italic>-<italic toggle="yes">spuI</italic> operons for polyamine uptake and utilization in <italic toggle="yes">Pseudomonas aeruginosa</italic> PAO1</article-title><source>J. Bacteriol.</source><year>2002</year><volume>184</volume><fpage>3765</fpage><lpage>3773</lpage><pub-id pub-id-type="doi">10.1128/JB.184.14.3765-3773.2002</pub-id><pub-id pub-id-type="pmid">12081945</pub-id><pub-id pub-id-type="pmcid">PMC135167</pub-id></element-citation></ref><ref id="B46-microorganisms-14-00078"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Holden</surname><given-names>M.T.</given-names></name>
<name name-style="western"><surname>Ram Chhabra</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>de Nys</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Stead</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Bainton</surname><given-names>N.J.</given-names></name>
<name name-style="western"><surname>Hill</surname><given-names>P.J.</given-names></name>
<name name-style="western"><surname>Manefield</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kumar</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Labatte</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>England</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Quorum-sensing cross talk: Isolation and chemical characterization of cyclic dipeptides from <italic toggle="yes">Pseudomonas aeruginosa</italic> and other gram-negative bacteria</article-title><source>Mol. Microbiol.</source><year>1999</year><volume>33</volume><fpage>1254</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1999.01577.x</pub-id><pub-id pub-id-type="pmid">10510239</pub-id></element-citation></ref><ref id="B47-microorganisms-14-00078"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Imberty</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Wimmerová</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Mitchell</surname><given-names>E.P.</given-names></name>
<name name-style="western"><surname>Gilboa-Garber</surname><given-names>N.</given-names></name>
</person-group><article-title>Structures of the lectins from <italic toggle="yes">Pseudomonas aeruginosa</italic>: Insight into the molecular basis for host glycan recognition</article-title><source>Microbes Infect.</source><year>2004</year><volume>6</volume><fpage>221</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2003.10.016</pub-id><pub-id pub-id-type="pmid">15049333</pub-id></element-citation></ref><ref id="B48-microorganisms-14-00078"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kuo</surname><given-names>S.H.</given-names></name>
<name name-style="western"><surname>Lau</surname><given-names>G.W.</given-names></name>
</person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic>-derived metabolites and volatile organic compounds: Impact on lung epithelial homeostasis and mucosal immune response</article-title><source>Front. Immunol.</source><year>2025</year><volume>16</volume><elocation-id>1553013</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2025.1553013</pub-id><pub-id pub-id-type="pmid">40552284</pub-id><pub-id pub-id-type="pmcid">PMC12183278</pub-id></element-citation></ref><ref id="B49-microorganisms-14-00078"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kuznetsova</surname><given-names>M.V.</given-names></name>
<name name-style="western"><surname>Karpunina</surname><given-names>T.I.</given-names></name>
</person-group><article-title>Cell-mediated hemolytic activity of nosocomial <italic toggle="yes">Pseudomonas Aeruginosa</italic> strains</article-title><source>Bull. Exp. Biol. Med.</source><year>2015</year><volume>159</volume><fpage>258</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1007/s10517-015-2936-3</pub-id><pub-id pub-id-type="pmid">26085361</pub-id></element-citation></ref><ref id="B50-microorganisms-14-00078"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Alqahtani</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kopel</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Hamood</surname><given-names>A.</given-names></name>
</person-group><article-title>The in vivo and in vitro assessment of pyocins in treating <italic toggle="yes">Pseudomonas aeruginosa</italic> infections</article-title><source>Antibiotics</source><year>2022</year><volume>11</volume><elocation-id>1366</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11101366</pub-id><pub-id pub-id-type="pmid">36290026</pub-id><pub-id pub-id-type="pmcid">PMC9598984</pub-id></element-citation></ref><ref id="B51-microorganisms-14-00078"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nguyen</surname><given-names>T.H.N.</given-names></name>
<name name-style="western"><surname>Szamosvari</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Böttcher</surname><given-names>T.</given-names></name>
</person-group><article-title>Synthesis of bacterial 2-alkyl-4(1H)-quinolone derivatives</article-title><source>Arkivoc</source><year>2021</year><volume>2021</volume><fpage>218</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.24820/ark.5550190.p011.547</pub-id></element-citation></ref><ref id="B52-microorganisms-14-00078"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Illakkiam</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Ponraj</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Shankar</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Muthusubramanian</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Rajendhran</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Gunasekaran</surname><given-names>P.</given-names></name>
</person-group><article-title>Identification and structure elucidation of a novel antifungal compound produced by <italic toggle="yes">Pseudomonas aeruginosa</italic> PGPR2 against <italic toggle="yes">Macrophomina phaseolina</italic></article-title><source>Appl. Biochem. Biotechnol.</source><year>2013</year><volume>171</volume><fpage>2176</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1007/s12010-013-0469-7</pub-id><pub-id pub-id-type="pmid">24037513</pub-id></element-citation></ref><ref id="B53-microorganisms-14-00078"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>El-Damasy</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name>
<name name-style="western"><surname>Nocentini</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Seo</surname><given-names>S.H.</given-names></name>
<name name-style="western"><surname>Eldehna</surname><given-names>W.M.</given-names></name>
<name name-style="western"><surname>Bang</surname><given-names>E.K.</given-names></name>
<name name-style="western"><surname>Supuran</surname><given-names>C.T.</given-names></name>
<name name-style="western"><surname>Keum</surname><given-names>G.</given-names></name>
</person-group><article-title>Discovery of new 6-ureido/amidocoumarins as highly potent and selective inhibitors for the tumour-relevant carbonic anhydrases IX and XII</article-title><source>J. Enzym. Inhib. Med. Chem.</source><year>2023</year><volume>38</volume><fpage>2154603</fpage><pub-id pub-id-type="doi">10.1080/14756366.2022.2154603</pub-id><pub-id pub-id-type="pmid">36728712</pub-id><pub-id pub-id-type="pmcid">PMC9897768</pub-id></element-citation></ref><ref id="B54-microorganisms-14-00078"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chougoni</surname><given-names>K.K.</given-names></name>
<name name-style="western"><surname>Neely</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Ding</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Oduah</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Lam</surname><given-names>V.T.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Koblinski</surname><given-names>J.E.</given-names></name>
<name name-style="western"><surname>Windle</surname><given-names>B.E.</given-names></name>
<name name-style="western"><surname>Palit Deb</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Deb</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Oncogenic mutant p53 sensitizes non-small cell lung cancer cells to proteasome inhibition via oxidative stress-dependent induction of mitochondrial apoptosis</article-title><source>Cancer Res. Commun.</source><year>2024</year><volume>4</volume><fpage>2685</fpage><lpage>2698</lpage><pub-id pub-id-type="doi">10.1158/2767-9764.CRC-23-0637</pub-id><pub-id pub-id-type="pmid">39302104</pub-id><pub-id pub-id-type="pmcid">PMC11474859</pub-id></element-citation></ref><ref id="B55-microorganisms-14-00078"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>García-Crespo</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>de Ávila</surname><given-names>A.I.</given-names></name>
<name name-style="western"><surname>Gallego</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Soria</surname><given-names>M.E.</given-names></name>
<name name-style="western"><surname>Durán-Pastor</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Somovilla</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Martínez-González</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Muñoz-Flores</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Mínguez</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Salar-Vidal</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Synergism between remdesivir and ribavirin leads to SARS-CoV-2 extinction in cell culture</article-title><source>Br. J. Pharmacol.</source><year>2024</year><volume>181</volume><fpage>2636</fpage><lpage>2654</lpage><pub-id pub-id-type="doi">10.1111/bph.16344</pub-id><pub-id pub-id-type="pmid">38616133</pub-id></element-citation></ref><ref id="B56-microorganisms-14-00078"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Han</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kang</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Morphine promotes the malignant biological behavior of non-small cell lung cancer cells through the MOR/Src/mTOR pathway</article-title><source>Cancer Cell Int.</source><year>2021</year><volume>21</volume><fpage>622</fpage><pub-id pub-id-type="doi">10.1186/s12935-021-02334-8</pub-id><pub-id pub-id-type="pmid">34823532</pub-id><pub-id pub-id-type="pmcid">PMC8613927</pub-id></element-citation></ref><ref id="B57-microorganisms-14-00078"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Keil</surname><given-names>V.C.</given-names></name>
<name name-style="western"><surname>Funke</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Zeug</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Schild</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Müller</surname><given-names>M.</given-names></name>
</person-group><article-title>Ratiometric high-resolution imaging of JC-1 fluorescence reveals the subcellular heterogeneity of astrocytic mitochondria</article-title><source>Pflug. Arch. Eur. J. Physiol.</source><year>2011</year><volume>462</volume><fpage>693</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1007/s00424-011-1012-8</pub-id><pub-id pub-id-type="pmcid">PMC3192276</pub-id><pub-id pub-id-type="pmid">21881871</pub-id></element-citation></ref><ref id="B58-microorganisms-14-00078"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Martin</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Busch</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Herrmann</surname><given-names>R.G.</given-names></name>
<name name-style="western"><surname>Wanner</surname><given-names>G.</given-names></name>
</person-group><article-title>Efficient preparation of plant chromosomes for high-resolution scanning electron microscopy</article-title><source>Chromosome Res.</source><year>1994</year><volume>2</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1007/BF01552801</pub-id><pub-id pub-id-type="pmid">7981946</pub-id></element-citation></ref><ref id="B59-microorganisms-14-00078"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Abdul Rahman</surname><given-names>M.S.</given-names></name>
<name name-style="western"><surname>Kanakarajan</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Selvaraj</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Kamalanathan</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Fatima</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Abudawood</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Siddiqi</surname><given-names>N.J.</given-names></name>
<name name-style="western"><surname>Alanazi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>de Lourdes Pereira</surname><given-names>M.</given-names></name>
</person-group><article-title>Elucidation of the anticancer mechanism of durian fruit (<italic toggle="yes">Durio zibethinus</italic>) pulp extract in human leukemia (HL-60) cancer cells</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><elocation-id>2417</elocation-id><pub-id pub-id-type="doi">10.3390/nu15102417</pub-id><pub-id pub-id-type="pmid">37242300</pub-id><pub-id pub-id-type="pmcid">PMC10221080</pub-id></element-citation></ref><ref id="B60-microorganisms-14-00078"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Agúndez</surname><given-names>J.A.G.</given-names></name>
<name name-style="western"><surname>García-Martín</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>García-Lainez</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Miranda</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Andreu</surname><given-names>I.</given-names></name>
</person-group><article-title>Photomutagenicity of chlorpromazine and its N-demethylated metabolites assessed by NGS</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>6879</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-63651-y</pub-id><pub-id pub-id-type="pmid">32327675</pub-id><pub-id pub-id-type="pmcid">PMC7181754</pub-id></element-citation></ref><ref id="B61-microorganisms-14-00078"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dela Ahator</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Sagar</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L.-H.</given-names></name>
</person-group><article-title>Nutrient availability and phage exposure alter the Quorum-Sensing and CRISPR-cas-controlled population dynamics of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Msystems</source><year>2022</year><volume>7</volume><fpage>e0009222</fpage><pub-id pub-id-type="doi">10.1128/msystems.00092-22</pub-id><pub-id pub-id-type="pmid">35699339</pub-id><pub-id pub-id-type="pmcid">PMC9426516</pub-id></element-citation></ref><ref id="B62-microorganisms-14-00078"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L.H.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Suppression of <italic toggle="yes">Pseudomonas aeruginosa</italic> type III secretion system by a novel calcium-responsive signaling pathway</article-title><source>iScience</source><year>2024</year><volume>27</volume><fpage>109690</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2024.109690</pub-id><pub-id pub-id-type="pmid">38660402</pub-id><pub-id pub-id-type="pmcid">PMC11039405</pub-id></element-citation></ref><ref id="B63-microorganisms-14-00078"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Afrdi</surname><given-names>M.B.</given-names></name>
<name name-style="western"><surname>Sardar</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Serdaroğlu</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Wadood Ali Shah</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Alsharif</surname><given-names>K.F.</given-names></name>
<name name-style="western"><surname>Khan</surname><given-names>H.</given-names></name>
</person-group><article-title>In silico ADMET and DFT analysis of methoxy substituted curcumin derivatives</article-title><source>Inorg. Chem. Commun.</source><year>2024</year><volume>168</volume><fpage>112943</fpage><pub-id pub-id-type="doi">10.1016/j.inoche.2024.112943</pub-id><pub-id pub-id-type="pmid">39067349</pub-id></element-citation></ref><ref id="B64-microorganisms-14-00078"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Valente</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Assis</surname><given-names>M.C.</given-names></name>
<name name-style="western"><surname>Alvim</surname><given-names>I.M.</given-names></name>
<name name-style="western"><surname>Pereira</surname><given-names>G.M.</given-names></name>
<name name-style="western"><surname>Plotkowski</surname><given-names>M.C.</given-names></name>
</person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> induces apoptosis in human endothelial cells</article-title><source>Microb. Pathog.</source><year>2000</year><volume>29</volume><fpage>345</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1006/mpat.2000.0400</pub-id><pub-id pub-id-type="pmid">11095919</pub-id></element-citation></ref><ref id="B65-microorganisms-14-00078"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lu</surname><given-names>J.-h.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>Z.-f.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name>
</person-group><article-title>The mitochondrial cyclophilin D/p53 complexation mediates doxorubicin-induced non-apoptotic death of A549 lung cancer cells</article-title><source>Mol. Cell. Biochem.</source><year>2014</year><volume>389</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s11010-013-1922-1</pub-id><pub-id pub-id-type="pmid">24343341</pub-id></element-citation></ref><ref id="B66-microorganisms-14-00078"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lei</surname><given-names>K.F.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>Z.M.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Impedimetric quantification of the formation process and the chemosensitivity of cancer cell colonies suspended in 3D environment</article-title><source>Biosens. Bioelectron.</source><year>2015</year><volume>74</volume><fpage>878</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/j.bios.2015.07.060</pub-id><pub-id pub-id-type="pmid">26241736</pub-id></element-citation></ref><ref id="B67-microorganisms-14-00078"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Moreno-Vargas</surname><given-names>L.M.</given-names></name>
<name name-style="western"><surname>Prada-Gracia</surname><given-names>D.</given-names></name>
</person-group><article-title>Cancer-targeting applications of cell-penetrating peptides</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>26</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.3390/ijms26010002</pub-id><pub-id pub-id-type="pmid">39795861</pub-id><pub-id pub-id-type="pmcid">PMC11720565</pub-id></element-citation></ref><ref id="B68-microorganisms-14-00078"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Taghizadeh-Hesary</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Akbari</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Bahadori</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Behnam</surname><given-names>B.</given-names></name>
</person-group><article-title>Targeted anti-mitochondrial therapy: The future of oncology</article-title><source>Genes</source><year>2022</year><volume>13</volume><elocation-id>1728</elocation-id><pub-id pub-id-type="doi">10.3390/genes13101728</pub-id><pub-id pub-id-type="pmid">36292613</pub-id><pub-id pub-id-type="pmcid">PMC9602426</pub-id></element-citation></ref><ref id="B69-microorganisms-14-00078"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zorova</surname><given-names>L.D.</given-names></name>
<name name-style="western"><surname>Popkov</surname><given-names>V.A.</given-names></name>
<name name-style="western"><surname>Plotnikov</surname><given-names>E.Y.</given-names></name>
<name name-style="western"><surname>Silachev</surname><given-names>D.N.</given-names></name>
<name name-style="western"><surname>Pevzner</surname><given-names>I.B.</given-names></name>
<name name-style="western"><surname>Jankauskas</surname><given-names>S.S.</given-names></name>
<name name-style="western"><surname>Babenko</surname><given-names>V.A.</given-names></name>
<name name-style="western"><surname>Zorov</surname><given-names>S.D.</given-names></name>
<name name-style="western"><surname>Balakireva</surname><given-names>A.V.</given-names></name>
<name name-style="western"><surname>Juhaszova</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Mitochondrial membrane potential</article-title><source>Anal. Biochem.</source><year>2018</year><volume>552</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2017.07.009</pub-id><pub-id pub-id-type="pmid">28711444</pub-id><pub-id pub-id-type="pmcid">PMC5792320</pub-id></element-citation></ref><ref id="B70-microorganisms-14-00078"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sivandzade</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Bhalerao</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Cucullo</surname><given-names>L.</given-names></name>
</person-group><article-title>Analysis of the mitochondrial membrane potential using the cationic JC-1 dye as a sensitive fluorescent probe</article-title><source>Bio-Protocol</source><year>2019</year><volume>9</volume><fpage>e3128</fpage><pub-id pub-id-type="doi">10.21769/BioProtoc.3128</pub-id><pub-id pub-id-type="pmid">30687773</pub-id><pub-id pub-id-type="pmcid">PMC6343665</pub-id></element-citation></ref><ref id="B71-microorganisms-14-00078"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kciuk</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Gielecinska</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Mujwar</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Kolat</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Kaluzinska-Kolat</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Celik</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Kontek</surname><given-names>R.</given-names></name>
</person-group><article-title>Doxorubicin-An agent with multiple mechanisms of anticancer activity</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>659</elocation-id><pub-id pub-id-type="doi">10.3390/cells12040659</pub-id><pub-id pub-id-type="pmid">36831326</pub-id><pub-id pub-id-type="pmcid">PMC9954613</pub-id></element-citation></ref><ref id="B72-microorganisms-14-00078"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Szwed</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kania</surname><given-names>K.D.</given-names></name>
<name name-style="western"><surname>Jozwiak</surname><given-names>Z.</given-names></name>
</person-group><article-title>Assessment of pro-apoptotic activity of doxorubicin-transferrin conjugate in cells derived from human solid tumors</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2016</year><volume>70</volume><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2015.10.020</pub-id><pub-id pub-id-type="pmid">26520467</pub-id></element-citation></ref><ref id="B73-microorganisms-14-00078"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hassan</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Islam</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Mu</surname><given-names>M.M.</given-names></name>
<name name-style="western"><surname>Ito</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Koide</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Mori</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Yoshida</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Yokochi</surname><given-names>T.</given-names></name>
</person-group><article-title>Lipopolysaccharide prevents doxorubicin-induced apoptosis in RAW 264.7 macrophage cells by inhibiting p53 activation</article-title><source>Mol. Cancer Res.</source><year>2005</year><volume>3</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-05-0046</pub-id><pub-id pub-id-type="pmid">16046548</pub-id></element-citation></ref><ref id="B74-microorganisms-14-00078"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Norton</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Adini</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Maiti</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Adini</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name>
</person-group><article-title>RIP1/RIP3/MLKL mediates myocardial function through necroptosis in experimental autoimmune myocarditis</article-title><source>Front. Cardiovasc. Med.</source><year>2021</year><volume>8</volume><elocation-id>696362</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2021.696362</pub-id><pub-id pub-id-type="pmid">34497836</pub-id><pub-id pub-id-type="pmcid">PMC8419468</pub-id></element-citation></ref><ref id="B75-microorganisms-14-00078"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Liebl</surname><given-names>M.P.</given-names></name>
<name name-style="western"><surname>Meister</surname><given-names>S.C.</given-names></name>
<name name-style="western"><surname>Frey</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Hendrich</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Klemmer</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Wohlfart</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Untucht</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Nuber</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Pohl</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Lakics</surname><given-names>V.</given-names></name>
</person-group><article-title>Robust LC3B lipidation analysis by precisely adjusting autophagic flux</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-03875-8</pub-id><pub-id pub-id-type="pmid">34996966</pub-id><pub-id pub-id-type="pmcid">PMC8742033</pub-id></element-citation></ref><ref id="B76-microorganisms-14-00078"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Witzgall</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Depke</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Empting</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Broenstrup</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Mueller</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Blankenfeldt</surname><given-names>W.</given-names></name>
</person-group><article-title>The alkylquinolone repertoire of <italic toggle="yes">Pseudomonas aeruginosa</italic> is linked to structural flexibility of the FabH-like 2-Heptyl-3-hydroxy-4(1H)-quinolone (PQS) biosynthesis enzyme PqsBC</article-title><source>ChemBiochem A Eur. J. Chem. Biol.</source><year>2018</year><volume>19</volume><fpage>1531</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1002/cbic.201800153</pub-id><pub-id pub-id-type="pmid">29722462</pub-id></element-citation></ref><ref id="B77-microorganisms-14-00078"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>McGrath</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Wade</surname><given-names>D.S.</given-names></name>
<name name-style="western"><surname>Pesci</surname><given-names>E.C.</given-names></name>
</person-group><article-title>Dueling quorum sensing systems in <italic toggle="yes">Pseudomonas aeruginosa</italic> control the production of the Pseudomonas quinolone signal (PQS)</article-title><source>FEMS Microbiol. Lett.</source><year>2004</year><volume>230</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/S0378-1097(03)00849-8</pub-id><pub-id pub-id-type="pmid">14734162</pub-id></element-citation></ref><ref id="B78-microorganisms-14-00078"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Linani</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Benarous</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Bou-Salah</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Yousfi</surname><given-names>M.</given-names></name>
</person-group><article-title>Hispidin, Harmaline, and Harmine as potent inhibitors of bovine xanthine oxidase: Gout treatment, in vitro, ADMET prediction, and SAR studies</article-title><source>Bioorg. Chem.</source><year>2021</year><volume>112</volume><fpage>104937</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2021.104937</pub-id><pub-id pub-id-type="pmid">33932770</pub-id></element-citation></ref><ref id="B79-microorganisms-14-00078"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Reen</surname><given-names>F.J.</given-names></name>
<name name-style="western"><surname>McGlacken</surname><given-names>G.P.</given-names></name>
<name name-style="western"><surname>O’Gara</surname><given-names>F.</given-names></name>
</person-group><article-title>The expanding horizon of alkyl quinolone signalling and communication in polycellular interactomes</article-title><source>FEMS Microbiol. Lett.</source><year>2018</year><volume>365</volume><fpage>fny076</fpage><pub-id pub-id-type="doi">10.1093/femsle/fny076</pub-id><pub-id pub-id-type="pmid">29718276</pub-id></element-citation></ref><ref id="B80-microorganisms-14-00078"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Liang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Sproule</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Haltli</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Marchbank</surname><given-names>D.H.</given-names></name>
<name name-style="western"><surname>Berrué</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Overy</surname><given-names>D.P.</given-names></name>
<name name-style="western"><surname>McQuillan</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Lanteigne</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Duncan</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Correa</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Discovery of a new natural product and a deactivation of a quorum sensing system by culturing a “Producer” bacterium with a heat-killed “Inducer” culture</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><elocation-id>3351</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.03351</pub-id><pub-id pub-id-type="pmid">30705672</pub-id><pub-id pub-id-type="pmcid">PMC6344404</pub-id></element-citation></ref><ref id="B81-microorganisms-14-00078"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Depke</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Franke</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Brönstrup</surname><given-names>M.</given-names></name>
</person-group><article-title>Clustering of MS(2) spectra using unsupervised methods to aid the identification of secondary metabolites from <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Chromatogr. B Anal. Technol. Biomed. Life Sci.</source><year>2017</year><volume>1071</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2017.06.002</pub-id><pub-id pub-id-type="pmid">28642031</pub-id></element-citation></ref><ref id="B82-microorganisms-14-00078"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Abdalla</surname><given-names>M.Y.</given-names></name>
<name name-style="western"><surname>Hoke</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Seravalli</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Switzer</surname><given-names>B.L.</given-names></name>
<name name-style="western"><surname>Bavitz</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Fliege</surname><given-names>J.D.</given-names></name>
<name name-style="western"><surname>Murphy</surname><given-names>P.J.</given-names></name>
<name name-style="western"><surname>Britigan</surname><given-names>B.E.</given-names></name>
</person-group><article-title><italic toggle="yes">Pseudomonas</italic> quinolone signal induces oxidative stress and inhibits heme oxygenase-1 expression in lung epithelial Cells</article-title><source>Infect. Immun.</source><year>2017</year><volume>85</volume><fpage>e00176-17</fpage><pub-id pub-id-type="doi">10.1128/IAI.00176-17</pub-id><pub-id pub-id-type="pmid">28630072</pub-id><pub-id pub-id-type="pmcid">PMC5563587</pub-id></element-citation></ref><ref id="B83-microorganisms-14-00078"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rieger</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Thierbach</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ommer</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Dienhart</surname><given-names>F.S.V.</given-names></name>
<name name-style="western"><surname>Fetzner</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Busch</surname><given-names>K.B.</given-names></name>
</person-group><article-title><italic toggle="yes">Pseudomonas</italic> quinolone signal molecule PQS behaves like a B Class inhibitor at the I(Q) site of mitochondrial complex I</article-title><source>FASEB Bioadv.</source><year>2020</year><volume>2</volume><fpage>188</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1096/fba.2019-00084</pub-id><pub-id pub-id-type="pmid">32161908</pub-id><pub-id pub-id-type="pmcid">PMC7059627</pub-id></element-citation></ref><ref id="B84-microorganisms-14-00078"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Supong</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Thawai</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Supothina</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Auncharoen</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Pittayakhajonwut</surname><given-names>P.</given-names></name>
</person-group><article-title>Antimicrobial and anti-oxidant activities of quinoline alkaloids from <italic toggle="yes">Pseudomonas aeruginosa</italic> BCC76810</article-title><source>Phytochem. Lett.</source><year>2016</year><volume>17</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.phytol.2016.07.007</pub-id></element-citation></ref><ref id="B85-microorganisms-14-00078"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Balthazar</surname><given-names>J.D.</given-names></name>
<name name-style="western"><surname>Soosaimanickam</surname><given-names>M.P.</given-names></name>
<name name-style="western"><surname>Emmanuel</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Krishnaraj</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Sheikh</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Alghafis</surname><given-names>S.F.</given-names></name>
<name name-style="western"><surname>Ibrahim</surname><given-names>H.M.</given-names></name>
</person-group><article-title>8-Hydroxyquinoline a natural chelating agent from <italic toggle="yes">Streptomyces</italic> spp. inhibits A549 lung cancer cell lines via BCL2/STAT3 regulating pathways</article-title><source>World J. Microbiol. Biotechnol.</source><year>2022</year><volume>38</volume><fpage>182</fpage><pub-id pub-id-type="doi">10.1007/s11274-022-03368-4</pub-id><pub-id pub-id-type="pmid">35953631</pub-id></element-citation></ref><ref id="B86-microorganisms-14-00078"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mori</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Yamashita</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Furihata</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Nagai</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Shin-Ya</surname><given-names>K.</given-names></name>
</person-group><article-title>Burkholone, a new cytotoxic antibiotic against IGF-I dependent cells from <italic toggle="yes">Burkholderia</italic> sp.</article-title><source>J. Antibiot.</source><year>2007</year><volume>60</volume><fpage>713</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1038/ja.2007.92</pub-id><pub-id pub-id-type="pmid">18057702</pub-id></element-citation></ref><ref id="B87-microorganisms-14-00078"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kamigiri</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Tokunaga</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Shibazaki</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Setiawan</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Rantiatmodjo</surname><given-names>R.M.</given-names></name>
<name name-style="western"><surname>Morioka</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name>
</person-group><article-title>YM-30059, a novel quinolone antibiotic produced by <italic toggle="yes">Arthrobacter</italic> sp.</article-title><source>J. Antibiot.</source><year>1996</year><volume>49</volume><fpage>823</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.49.823</pub-id><pub-id pub-id-type="pmid">8823519</pub-id></element-citation></ref><ref id="B88-microorganisms-14-00078"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bultel-Poncé</surname><given-names>V.V.</given-names></name>
<name name-style="western"><surname>Berge</surname><given-names>J.P.</given-names></name>
<name name-style="western"><surname>Debitus</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Nicolas</surname><given-names>J.L.</given-names></name>
<name name-style="western"><surname>Guyot</surname><given-names>M.</given-names></name>
</person-group><article-title>Metabolites from the sponge-associated bacterium <italic toggle="yes">Pseudomonas</italic> species</article-title><source>Mar. Biotechnol.</source><year>1999</year><volume>1</volume><fpage>384</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/PL00011792</pub-id><pub-id pub-id-type="pmid">10489417</pub-id></element-citation></ref><ref id="B89-microorganisms-14-00078"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ding</surname><given-names>W.Q.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Vaught</surname><given-names>J.L.</given-names></name>
<name name-style="western"><surname>Yamauchi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Lind</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Anticancer activity of the antibiotic clioquinol</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>3389</fpage><lpage>3395</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3577</pub-id><pub-id pub-id-type="pmid">15833873</pub-id></element-citation></ref><ref id="B90-microorganisms-14-00078"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Xiao</surname><given-names>J.</given-names></name>
</person-group><article-title>Quinolone hybrids and their anti-cancer activities: An overview</article-title><source>Eur. J. Med. Chem.</source><year>2019</year><volume>165</volume><fpage>59</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.01.017</pub-id><pub-id pub-id-type="pmid">30660827</pub-id></element-citation></ref><ref id="B91-microorganisms-14-00078"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Bonfield</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Tartakoff</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Non-apoptotic toxicity of <italic toggle="yes">Pseudomonas aeruginosa</italic> toward murine cells</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e54245</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0054245</pub-id><pub-id pub-id-type="pmid">23358229</pub-id><pub-id pub-id-type="pmcid">PMC3554662</pub-id></element-citation></ref><ref id="B92-microorganisms-14-00078"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Arango</surname><given-names>J.P.B.</given-names></name>
<name name-style="western"><surname>Rodriguez</surname><given-names>D.Y.M.</given-names></name>
<name name-style="western"><surname>Cruz</surname><given-names>S.L.</given-names></name>
<name name-style="western"><surname>Ocampo</surname><given-names>G.T.</given-names></name>
</person-group><article-title>In silico evaluation of pharmacokinetic properties and molecular docking for the identification of potential anticancer compounds</article-title><source>Comput. Biol. Chem.</source><year>2025</year><volume>120</volume><fpage>108626</fpage><pub-id pub-id-type="doi">10.1016/j.compbiolchem.2025.108626</pub-id><pub-id pub-id-type="pmid">40803051</pub-id></element-citation></ref><ref id="B93-microorganisms-14-00078"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Smith</surname><given-names>D.A.</given-names></name>
<name name-style="western"><surname>Di</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Kerns</surname><given-names>E.H.</given-names></name>
</person-group><article-title>The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>929</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1038/nrd3287</pub-id><pub-id pub-id-type="pmid">21119731</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="microorganisms-14-00078-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Isolation and structural characterization of JH62, an anticancer compound from <italic toggle="yes">Pa</italic>. (<bold>A</bold>) Flowchart for extraction and isolation of anticancer compounds from <italic toggle="yes">Pa</italic> PAO1. (<bold>B</bold>) Microscopic analysis of the effect of JH62 fraction on the growth of A549 lung cancer cells. (<bold>C</bold>) <sup>1</sup>H NMR spectrum of JH62. (<bold>D</bold>) <sup>13</sup>C NMR spectrum of JH62. (<bold>E</bold>) HMBC (<sup>1</sup>H−<sup>13</sup>C Heteronuclear Multiple Bond Correlation) spectrum of JH62. (<bold>F</bold>) HMQC (<sup>1</sup>H-<sup>13</sup>C Heteronuclear Multiple Quantum Coherence) spectrum of JH62. (<bold>G</bold>) Chemical structure and molecular formula of the compound JH62.</p></caption><graphic orientation="portrait" position="float" xlink:href="microorganisms-14-00078-g001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig id="microorganisms-14-00078-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>JH62 induces cancer cell death and inhibits tumor growth. (<bold>A</bold>,<bold>B</bold>) JH62 inhibits the growth of A549 lung cancer cells. Microscopic images of A549 cells treated with JH62 or DOX. Cells were treated with 25 μM JH62 or 5 μM DOX for 0, 4, 8, and 24 h. Ctrl represents the solvent control group treated with an equal volume of DMSO (<bold>A</bold>); Effect of JH62 on the viability of A549 cells. Cells were treated with 12.5, 25, and 50 μM JH62 for 24, 32, and 48 h. The 0 μM group represents the solvent control (equal volume of DMSO) (<bold>B</bold>). Colony formation (<bold>C</bold>) and colony number quantification (<bold>D</bold>) of A549 cells with 6.3 μM or 12.5 μM JH62 treatment. IC<sub>50</sub> values for JH62 (<bold>E</bold>) and DOX (<bold>F</bold>) against different cell lines. MEF, mouse embryonic fibroblast cell lines. AML12, mouse liver cell lines. WI-38, human lung fibroblast cell lines. THLE-2: human liver epithelial cell lines. HEPG2, human liver cancer cell lines. HEP3B, human hepatoma cell lines. BxPC3, human pancreatic cancer cell lines. U87, human primary glioblastoma cell lines. DU145, human prostate cancer cell lines. A549, alveolar adenocarcinoma cell lines. MCF7, human breast cancer cell lines. Hela, human cervical cancer cell lines. HCT116, human colon cancer cell lines. The appearance (<bold>G</bold>), weight (<bold>H</bold>) and volume (<bold>I</bold>) of tumors from A549 injected xenograft mouse model with 10 mg/kg JH62 treatment. <italic toggle="yes">n</italic> = 15. Ctrl, Dimethyl sulfoxide (DMSO) as solvent controls. Statistical analysis was performed using one way ANOVA (<bold>B</bold>,<bold>D</bold>–<bold>F</bold>) or Student’s <italic toggle="yes">t</italic>-test (<bold>H</bold>). * <italic toggle="yes">p</italic> &lt; 0.05; ** <italic toggle="yes">p</italic> &lt; 0.01; *** <italic toggle="yes">p</italic> &lt; 0.001; **** <italic toggle="yes">p</italic> &lt; 0.0001. Bars in (<bold>E</bold>,<bold>F</bold>) sharing the same letter are not significantly different, whereas bars with different letters indicate statistically significant differences (<italic toggle="yes">p</italic> &lt; 0.05). Error bars indicated standard deviations.</p></caption><graphic orientation="portrait" position="float" xlink:href="microorganisms-14-00078-g002.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig id="microorganisms-14-00078-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>JH62 suppressed mitochondrial function. Mitochondrial JC-1 aggregate detection of mitochondria in JH62-treated A549 cells (<bold>A</bold>), green fluorescence indicates the monomeric form of the JC-1 dye, red fluorescence represents the aggregated form of JC-1, and the merged images show the overlay of the green and red fluorescence signals. MitoTracker Red confocal images (<bold>B</bold>) and transmission electron microscopic analysis (<bold>C</bold>) of mitochondria in JH62-treated A549 cells. Red arrows denote mitochondria. Ctrl, Dimethyl sulfoxide (DMSO) as solvent controls.</p></caption><graphic orientation="portrait" position="float" xlink:href="microorganisms-14-00078-g003.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig id="microorganisms-14-00078-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>JH62 induces autophagy in A549 cells. (<bold>A</bold>) Phase contrast microscope images of DOX- or JH62-treated A549 cells. A549 cells were treated with 5 μM DOX or 25 μM JH62 for 48 h. (<bold>B</bold>) The chromosomes image of the DOX- or JH62-treated A549 cells. Before being stained and imaged, A549 cells were treated with 5 μM DOX or 25 μM JH62 for 6 h. (<bold>C</bold>) The genomic DNA electrophoresis assays of DOX- (1 and 5 μM) or JH62-treated (5, 25, and 100 μM) A549 cells. (<bold>D</bold>) Comet assay of DNA obtained from DOX- and JH62-treated A549 cells over 1, 8, and 12 h. (<bold>E</bold>) The apoptosis or necrosis inhibitor cannot block the A549 cell death induced by JH62. Nec-1, necrosis inhibitor. zVAD-fmk, apoptosis inhibitor. Phase contrast microscope images of A549 cells treated with DMSO (Ctrl), Nec-1, zVAD-fmk, JH62, JH62 + Nec-1, JH62 + zVAD-fmk, and JH62 + zVAD-fmk + Nec-1. (<bold>F</bold>) JH62 treatment induces autophagosome formation in A549 lung cancer cells. A549 lung cancer cells were treated with DMSO (Ctrl) or 25 μM JH62 for 24 h. Autophagosomes are indicated by red arrows. (<bold>G</bold>) Immunofluorescence analysis of LC3B in JH62-treated A549 cells. Cells were treated with JH62 for 1, 2, 4, 8, 16, and 24 h. Green fluorescence represents LC3B immunofluorescence signals, and red arrows denote LC3B punctate fluorescence signals. Ctrl represents the DMSO solvent control group.</p></caption><graphic orientation="portrait" position="float" xlink:href="microorganisms-14-00078-g004.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig id="microorganisms-14-00078-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>The <italic toggle="yes">pqs</italic> gene cluster in <italic toggle="yes">Pa</italic> mediates the biosynthesis of JH62. (<bold>A</bold>) The quantitative analysis of extracellular JH62 produced by <italic toggle="yes">Pa</italic> PAO1 at various growth periods. The blue column represents the extracellular production of JH62. The red curve represents the OD<sub>600</sub> value of <italic toggle="yes">Pa</italic> culture. The maximum yield sample was defined as 100%. (<bold>B</bold>) The intracellular and extracellular production of JH62 in <italic toggle="yes">Pa</italic> PAO1 at 4, 8, and 12 h after incubation. The maximum yield sample was defined as 100%. (<bold>C</bold>) The production of JH62 in Δ<italic toggle="yes">pqs</italic> mutants and corresponding complemented strains. The yield of PAO1 WT was defined as 100%. (<bold>D</bold>) The analysis of rate-limiting enzyme in JH62 biosynthesis. WT/pBBR1, <italic toggle="yes">Pa</italic> PAO1 WT strain with empty pBBR1 plasmid./<italic toggle="yes">pqs</italic>, <italic toggle="yes">Pa</italic> PAO1 WT strain with corresponding <italic toggle="yes">pqs</italic> gene overexpressed pBBR1 plasmid. The yield of WT/pBBR1 was defined as 100%. (<bold>E</bold>) The production of JH62 in different <italic toggle="yes">Pa</italic> WT strains. The yield of PAO1 was defined as 100%. (<bold>F</bold>) The relative production of JH62 in PAO1-1 <italic toggle="yes">pqs</italic>-overexpressed strains compared to WT PAO1. pBBR1, empty vector as the negative control. The yield of WT PAO1 was defined as 100%. (<bold>G</bold>) Effect of exogenous JH62 on the transcriptional level of the <italic toggle="yes">pqs</italic> gene cluster in Δ<italic toggle="yes">pqsA</italic> mutant strain; data were analyzed by permutation test. ns, no significance; * <italic toggle="yes">p</italic> &lt; 0.05. (<bold>H</bold>) The production of JH62 in <italic toggle="yes">rhl</italic> and <italic toggle="yes">las</italic> mutants and complemented strains. The yield of PAO1 WT was defined as 100%. Statistical analysis was performed using one way ANOVA. ns, no significance; * <italic toggle="yes">p</italic> &lt; 0.05; ** <italic toggle="yes">p</italic> &lt; 0.01; *** <italic toggle="yes">p</italic> &lt; 0.001; **** <italic toggle="yes">p</italic> &lt; 0.0001. <italic toggle="yes">n</italic> = 5. Error bars indicate standard deviations.</p></caption><graphic orientation="portrait" position="float" xlink:href="microorganisms-14-00078-g005.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><table-wrap id="microorganisms-14-00078-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">microorganisms-14-00078-t001_Table 1</object-id><label>Table 1</label><caption><p>The key metabolites of <italic toggle="yes">Pa</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Metabolite</th><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Function</th><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th></tr></thead><tbody><tr><td align="center" colspan="1" rowspan="1" valign="middle">Pyocyanin</td><td align="center" colspan="1" rowspan="1" valign="middle">Oxidative stress; Host damage</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B30-microorganisms-14-00078">30</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Phenazines</td><td align="center" colspan="1" rowspan="1" valign="middle">Redox balance; Persistence</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B31-microorganisms-14-00078">31</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Rhamnolipids</td><td align="center" colspan="1" rowspan="1" valign="middle">Biofilm formation; Membrane disruption</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B32-microorganisms-14-00078">32</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Pyoverdine</td><td align="center" colspan="1" rowspan="1" valign="middle">Iron acquisition; Virulence regulation</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B33-microorganisms-14-00078">33</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Pyochelin</td><td align="center" colspan="1" rowspan="1" valign="middle">Iron acquisition</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B34-microorganisms-14-00078">34</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Hydrogen cyanide</td><td align="center" colspan="1" rowspan="1" valign="middle">Acute virulence; Respiratory inhibition</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B35-microorganisms-14-00078">35</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Acyl-homoserine lactone</td><td align="center" colspan="1" rowspan="1" valign="middle">Quorum sensing</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B36-microorganisms-14-00078">36</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Quinolones</td><td align="center" colspan="1" rowspan="1" valign="middle">Quorum sensing; Iron acquisition; Cytotoxicity</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B37-microorganisms-14-00078">37</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Alginate</td><td align="center" colspan="1" rowspan="1" valign="middle">Antibiotic tolerance; Chronic infection</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B38-microorganisms-14-00078">38</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Pel polysaccharide</td><td align="center" colspan="1" rowspan="1" valign="middle">Surface attachment; Cell aggregation</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B39-microorganisms-14-00078">39</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Psl polysaccharide</td><td align="center" colspan="1" rowspan="1" valign="middle">Biofilm initiation and maintenance</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B40-microorganisms-14-00078">40</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Acetate</td><td align="center" colspan="1" rowspan="1" valign="middle">Energy balance; Metabolic flexibility</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B41-microorganisms-14-00078">41</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Succinate</td><td align="center" colspan="1" rowspan="1" valign="middle">Preferred carbon source; Growth optimization</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B42-microorganisms-14-00078">42</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Glutamate</td><td align="center" colspan="1" rowspan="1" valign="middle">Growth and stress tolerance</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B43-microorganisms-14-00078">43</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Branched-chain amino acids</td><td align="center" colspan="1" rowspan="1" valign="middle">Environmental adaptability</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B44-microorganisms-14-00078">44</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Polyamine</td><td align="center" colspan="1" rowspan="1" valign="middle">Stress tolerance; Biofilm stability</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B45-microorganisms-14-00078">45</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Cyclic dipeptides</td><td align="center" colspan="1" rowspan="1" valign="middle">Quorum sensing; interspecies interactions</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B46-microorganisms-14-00078">46</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Lectins</td><td align="center" colspan="1" rowspan="1" valign="middle">Host cell attachment; Biofilm stability;</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B47-microorganisms-14-00078">47</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Volatile organic compounds</td><td align="center" colspan="1" rowspan="1" valign="middle">Virulence</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B48-microorganisms-14-00078">48</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Hemolysin</td><td align="center" colspan="1" rowspan="1" valign="middle">Cell lysis; Tissue damage; Virulence</td><td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B49-microorganisms-14-00078">49</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pyocins</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Intraspecies competition; Niche dominance</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B50-microorganisms-14-00078">50</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="microorganisms-14-00078-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">microorganisms-14-00078-t002_Table 2</object-id><label>Table 2</label><caption><p>The IC<sub>50</sub> value and ZIP Score of JH62 and DOX against different cell lines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Cell Lines</th><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">JH62<break/>IC<sub>50</sub> (μM)</th><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">DOX<break/>IC<sub>50</sub> (μM)</th><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">JH62/DOX<break/>ZIP Score</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1" valign="middle">Non-cancer cell lines</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">MEF</td><td align="center" colspan="1" rowspan="1" valign="middle">47.2 ± 4.8</td><td align="center" colspan="1" rowspan="1" valign="middle">3.9 ± 0.4</td><td align="center" colspan="1" rowspan="1" valign="middle">5.77 ± 2.17</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">AML12</td><td align="center" colspan="1" rowspan="1" valign="middle">37.1 ± 0.7</td><td align="center" colspan="1" rowspan="1" valign="middle">5.1 ± 1.3</td><td align="center" colspan="1" rowspan="1" valign="middle">5.83 ± 0.27</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">WI-38</td><td align="center" colspan="1" rowspan="1" valign="middle">44.1 ± 0.4</td><td align="center" colspan="1" rowspan="1" valign="middle">1.9 ± 0.3</td><td align="center" colspan="1" rowspan="1" valign="middle">4.91 ± 0.67</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">THLE-2</td><td align="center" colspan="1" rowspan="1" valign="middle">27.3 ± 4.9</td><td align="center" colspan="1" rowspan="1" valign="middle">1.2 ± 0.1</td><td align="center" colspan="1" rowspan="1" valign="middle">12.06 ± 1.79</td></tr><tr><td align="left" colspan="4" rowspan="1" valign="middle">Cancer cell lines</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">HEPG2</td><td align="center" colspan="1" rowspan="1" valign="middle">17.2 ± 0.6</td><td align="center" colspan="1" rowspan="1" valign="middle">0.8 ± 0.1</td><td align="center" colspan="1" rowspan="1" valign="middle">8.31 ± 3.96</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">HEP3B</td><td align="center" colspan="1" rowspan="1" valign="middle">10.8 ± 0.4</td><td align="center" colspan="1" rowspan="1" valign="middle">3.3 ± 0.2</td><td align="center" colspan="1" rowspan="1" valign="middle">14.61 ± 1.18</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">BxPC3</td><td align="center" colspan="1" rowspan="1" valign="middle">15.0 ± 0.4</td><td align="center" colspan="1" rowspan="1" valign="middle">1.9 ± 0.1</td><td align="center" colspan="1" rowspan="1" valign="middle">13.79 ± 1.08</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">U87</td><td align="center" colspan="1" rowspan="1" valign="middle">10.0 ± 0.2</td><td align="center" colspan="1" rowspan="1" valign="middle">1.4 ± 1.0</td><td align="center" colspan="1" rowspan="1" valign="middle">13.85 ± 0.32</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">DU145</td><td align="center" colspan="1" rowspan="1" valign="middle">13.8 ± 3.3</td><td align="center" colspan="1" rowspan="1" valign="middle">1.9 ± 0.2</td><td align="center" colspan="1" rowspan="1" valign="middle">20.33 ± 6.66</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">A549</td><td align="center" colspan="1" rowspan="1" valign="middle">14.8 ± 0.1</td><td align="center" colspan="1" rowspan="1" valign="middle">2.1 ± 0.5</td><td align="center" colspan="1" rowspan="1" valign="middle">19.66 ± 5.28</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">MCF7</td><td align="center" colspan="1" rowspan="1" valign="middle">13.9 ± 1.3</td><td align="center" colspan="1" rowspan="1" valign="middle">1.2 ± 0.5</td><td align="center" colspan="1" rowspan="1" valign="middle">5.31 ± 3.23</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">HeLa</td><td align="center" colspan="1" rowspan="1" valign="middle">13.6 ± 2.7</td><td align="center" colspan="1" rowspan="1" valign="middle">0.7 ± 0.7</td><td align="center" colspan="1" rowspan="1" valign="middle">11.72 ± 3.18</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HCT116</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8.6 ± 0.1</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3.9 ± 0.7</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12.19 ± 2.30</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as the mean ± SD. IC<sub>50</sub>: Half maximal inhibitory concentration. ZIP Score ≤ 10: additive; ZIP Score &gt; 10: synergistic.</p></fn></table-wrap-foot></table-wrap><table-wrap id="microorganisms-14-00078-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">microorganisms-14-00078-t003_Table 3</object-id><label>Table 3</label><caption><p>The drug-likeness and ADMET properties evaluation of JH62.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Properties</th><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">JH62</th></tr></thead><tbody><tr><td align="center" colspan="2" rowspan="1" valign="middle">Physicochemical properties</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Molecular Weight</td><td align="center" colspan="1" rowspan="1" valign="middle">325.24</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">No. heavy atoms</td><td align="center" colspan="1" rowspan="1" valign="middle">24</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">No. aromatic heavy atom</td><td align="center" colspan="1" rowspan="1" valign="middle">10</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">No. rotatable bonds</td><td align="center" colspan="1" rowspan="1" valign="middle">11</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">No. H-bond donors</td><td align="center" colspan="1" rowspan="1" valign="middle">1</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">No. H-bond acceptors</td><td align="center" colspan="1" rowspan="1" valign="middle">1</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Molar refractivity</td><td align="center" colspan="1" rowspan="1" valign="middle">106.74</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">TPSA</td><td align="center" colspan="1" rowspan="1" valign="middle">32.86 Å<sup>2</sup></td></tr><tr><td align="center" colspan="2" rowspan="1" valign="middle">Medicinal chemistry</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">PAINS</td><td align="center" colspan="1" rowspan="1" valign="middle">0</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Brenk</td><td align="center" colspan="1" rowspan="1" valign="middle">1</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Synthetic accessibility</td><td align="center" colspan="1" rowspan="1" valign="middle">3.14</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Lipinski rule</td><td align="center" colspan="1" rowspan="1" valign="middle">Accepted</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Golden triangle rule</td><td align="center" colspan="1" rowspan="1" valign="middle">Accepted</td></tr><tr><td align="center" colspan="2" rowspan="1" valign="middle">Absorption</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Intestinal permeability</td><td align="center" colspan="1" rowspan="1" valign="middle">−5.004 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">MDCK permeability</td><td align="center" colspan="1" rowspan="1" valign="middle">−4.703 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">PAMPA</td><td align="center" colspan="1" rowspan="1" valign="middle">0.003 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Human intestinal absorption</td><td align="center" colspan="1" rowspan="1" valign="middle">0.065 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Oral bioavailability</td><td align="center" colspan="1" rowspan="1" valign="middle">0.122 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="2" rowspan="1" valign="middle">Distribution</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">BBB</td><td align="center" colspan="1" rowspan="1" valign="middle">0.0005 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">VDss</td><td align="center" colspan="1" rowspan="1" valign="middle">0.5690 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">PPB</td><td align="center" colspan="1" rowspan="1" valign="middle">99.0% <named-content content-type="color:red">●</named-content></td></tr><tr><td align="center" colspan="2" rowspan="1" valign="middle">Metabolism</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">CYP1A2 inhibitor</td><td align="center" colspan="1" rowspan="1" valign="middle">Inhibitor</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">CYP2C9 inhibitor</td><td align="center" colspan="1" rowspan="1" valign="middle">Inhibitor</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">CYP2D6 inhibitor</td><td align="center" colspan="1" rowspan="1" valign="middle">Inhibitor</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">CYP3A4 inhibitor</td><td align="center" colspan="1" rowspan="1" valign="middle">Inhibitor</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">CYP2B6 inhibitor</td><td align="center" colspan="1" rowspan="1" valign="middle">Inhibitor</td></tr><tr><td align="center" colspan="2" rowspan="1" valign="middle">Excretion</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Plasma clearance</td><td align="center" colspan="1" rowspan="1" valign="middle">4.937 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">The half-life</td><td align="center" colspan="1" rowspan="1" valign="middle">0.352</td></tr><tr><td align="center" colspan="2" rowspan="1" valign="middle">Toxicity</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Drug-induced liver injury</td><td align="center" colspan="1" rowspan="1" valign="middle">0.179 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">AMES Toxicity</td><td align="center" colspan="1" rowspan="1" valign="middle">0.132 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Rat oral acute toxicity</td><td align="center" colspan="1" rowspan="1" valign="middle">0.181 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Carcinogenicity</td><td align="center" colspan="1" rowspan="1" valign="middle">0.186 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Eye corrosion</td><td align="center" colspan="1" rowspan="1" valign="middle">0.014 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Drug-induced Neurotoxicity</td><td align="center" colspan="1" rowspan="1" valign="middle">0.258 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Genotoxicity</td><td align="center" colspan="1" rowspan="1" valign="middle">0.014 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">RPMI-8226 Immunotoxicity</td><td align="center" colspan="1" rowspan="1" valign="middle">0.132 <named-content content-type="color:#00B050">●</named-content></td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ototoxicity</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.342 <named-content content-type="color:#FFD966">●</named-content></td></tr></tbody></table><table-wrap-foot><fn><p>TPSA: Topological Polar Surface Area; PAINS: Pan Assay Interference Structures; MDCK: Madin–Darby Canine Kidney cells; PAMPA: The Parallel Artificial Membrane Permeability Assay; BBB: Blood–brain barrier penetration; VDss: Volume of distribution at steady state; PPB: Plasma protein binding. Colored label: The compound is evaluated as excellent (Green), medium (Yellow), or poor (Red) in the corresponding aspect.</p></fn></table-wrap-foot></table-wrap></floats-group></article>